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ABSTRACT 
Xanthine oxidase (XO) is a pivotal enzyme in purine metabolism. As the end 
product, overproduction of uric acid may lead to hyperuricemia and gout disease. This 
research was conducted to assess the antioxidant potential and xanthine oxidase 
inhibitory activity of Pandanus amaryllifolius Roxb. P. amaryllifolius was extracted 
with hexane, petroleum ether, chloroform, methanol and distilled water, where the crude 
extracts were named as PA-H, PA-PE, PA-C, PA-M, and PA-W respectively. The TLC 
result showed the presence of terpenoids in all of the extracts. The total phenolic and 
flavonoid contents were conducted in P. amaryllifolius extracts. PA-W showed the 
highest TPC with 12.88 ± 0.43 mg GAE/g of dry extract whereas PA-PE showed the 
highest TFC with 15.02 ± 0.58 mg QE/g of dry extract. Antioxidant activities were 
performed on P. amaryllifolius extracts and PA-W generally exhibited the highest 
activity. In DPPH, metal chelating, and hydrogen peroxide assay, all extracts displayed 
low scavenging activity. However, each extract possessed steady increase in inhibition 
activity within their concentration range. PA-W showed the highest activity in DPPH 
(>240 g/mL), metal chelating (>160 g/mL), and hydrogen peroxide assay (>320 
g/mL). PA-M showed the highest activity in FRAP assay (64.39 ± 2.79 mmol Fe2+/g 
of dry extract). TPC revealed positive significant correlation with DPPH (r = 0.972, 
P<0.01), FRAP (r = 0.964, P<0.01), and hydrogen peroxide assay (r = 0.898, P<0.05), 
but no correlation with metal chelating assay (r = 0.382) and in vitro XO inhibitory 
activity (r = 0.809). TFC showed negative correlation with all assays. In in vitro XO 
inhibitory activity, PA-W displayed the highest activity (>100 g/mL). In in vivo XO 
inhibitory activity, acute toxicity test of PA-W tested at 2 g/kg body weight showed no 
signs of toxicity and mortality after 14 days. The treatment with PA-W showed 
significant (P<0.001) decrease in serum uric acid level and XO activity. At the dose of 
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1000 mg/kg body weight and 500 mg/kg body weight, the serum uric acid level were 
2.55 ± 2.23 mg/dL and 6.08 ± 1.00 mg/dL, whereas the XO activity were 3.84 ± 0.68 
mu/mL and 6.35 ± 0.87 mu/mL, in hyperuricemic rats. Allopurinol standard exhibited 
serum uric acid level and XO activity of 1.72 ± 1.01 mg/dL and 1.06 ± 0.21 mu/mL 
respectively. Thus, the results of this finding support the use of P. amaryllifolius in 
reducing uric acid for the treatment of hyperuricemia and rheumatoid arthritis. 
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ABSTRAK 
Xanthine oksidase ialah satu enzim penting dalam metabolism purin. Sebagai produk 
akhir, penghasilan berlebihan asid urik boleh mengakibatkan penyakit hiperurisemia 
dan gout. Kajian ini dijalankan untuk menilai potensi antioksidan dan aktiviti 
perencatan xanthine oksidase Pandanus amaryllifolius Roxb. P. amaryllifolius telah 
diekstrak dengan heksana, petroleum eter, klorofom, metanol dan air suling, di mana 
ekstrak mentah itu dinamakan sebagai PA-H, PA-PE, PA-C, PA-M, dan PA-W masing-
masing. Hasil TLC menunjukkan kehadiran terpenoid dalam semua ekstrak. Jumlah 
kandungan fenolik dan flavonoid telah dijalankan ke atas ekstrak P. amaryllifolius. PA-
W menunjukkan TPC tertinggi dengan 12.88 ± 0.43 mg GAE/g ekstrak kering manakala 
PA-PE menunjukkan TFC tertinggi dengan 15.02 ± 0.58 mg QE/g ekstrak kering. 
Aktiviti antioksidan telah dijalankan ke atas ekstrak P. amaryllifolius dan PA-W 
umumnya menunjukkan aktiviti tertinggi. Dalam asei DPPH, logam pengkelat dan 
hidrogen peroksida, semua ekstrak memaparkan aktiviti memerangkap yang rendah. 
Namun, setiap ekstrak menunjukkan peningkatan kukuh dalam aktiviti perencatan 
dalam julat kepekatan mereka. PA-W menunjukkan aktiviti tertinggi dalam asei DPPH 
(>240 g/mL), logam pengkelat (>160 g/mL), dan hidrogen peroksida (>320 g/mL). 
PA-M menunjukkan aktiviti tertinggi dalam asei FRAP (64.39 ± 2.79 mmol Fe
2+
/g 
ekstrak kering). TPC menunjukkan kolerasi positif signifikan dengan asei DPPH (r = 
0.972, P<0.01), FRAP (r = 0.964, P<0.01), dan hidrogen peroksida (r = 0.898, 
P<0.05), tetapi tiada kolerasi dengan asei logam pengkelat (r = 0.382) dan aktiviti 
perencatan XO in vitro (r = 0.809). TFC menunjukkan kolerasi negatif dengan semua 
asei. Dalam aktiviti perencatan XO in vitro, PA-W menunjukkan aktiviti tertinggi (>100 
g/mL). Dalam aktiviti perencatan XO in vivo, ujian ketoksikan akut PA-W diuji pada 2 
g/kg berat badan tidak menunjukkan tanda-tanda keracunan dan kematian selepas 14 
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hari. Rawatan dengan PA-W menunjukkan penurunan signifikan (P<0.001) dalam tahap 
asid urik dan aktiviti XO serum. Pada dos 1000 mg/kg berat badan dan 500 mg/kg berat 
badan, tahap asid urik serum ialah 2.55 ± 2.23 mg/dL dan 6.08 ± 1.00 mg/dL manakala 
aktiviti XO ialah 3.84 ± 0.68 mu/mL dan 6.35 ± 0.87 mu/mL, pada tikus hiperurisemik. 
Piawai allopurinol memaparkan tahap asid urik dan aktiviti XO serum 1.72 ± 1.01 
mg/dL dan 1.06 ± 0.21 mu/mL masing-masing. Oleh itu, keputusan daripada penemuan 
ini menyokong penggunaan P. amaryllifolius dalam mengurangkan asid urik untuk 
rawatan hiperurisemia dan radang sendi. 
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CHAPTER 1: INTRODUCTION 
 
Xanthine oxidase (XO) which is in a form of molybdoflavin protein xanthine 
oxidoreductase (XOR) serves a crucial role in the degradation of purine in humans 
(Hille, 2005). The final metabolite in purine catabolism in humans is uric acid (Lima et 
al., 2015). In the process, hypoxanthine is converted to xanthine and xanthine is 
converted to uric acid via enzymatic reaction of xanthine oxidase (Mamat et al., 2014). 
Uric acid generated is then discharged in the urine. Excessive or little manufacture of 
uric acid could consequently result in hyperuricemia and gout (Richette & Bardin, 
2010). 
According to Boffetta et al. (2009) hyperuricemia is a prominent threat factor for 
gout, hypertension as well as diabetes. The basis of the disease is uric acid 
crystallization and deposition in joints and neighboring tissues. Since uric acid 
overproduction is the key causation of hyperuricemia, the ultimate assuring target for 
therapeutic remedy of this disorder is xanthine oxidase (Richette & Bardin, 2010). 
According to Umamaheswari et al. (2007) 5 to 30% of worldwide human population 
experiences uric acid overproduction or underexcretion. Gout which is described as a 
steady increase in plasma urate levels has a prevalence of about 1% whereas chronic 
kidney disorder that is usually linked to hyperuricemia has a prevalence of about 5% 
(Richette & Bardin, 2010). 
Treatment of illness related to hyperuricemia has been tackled by the means of 
keeping the precipitation of plasma urate concentrations low as well as getting rid of the 
present urate crystals (Kumar & Azmi, 2014). According to Richette & Bardin (2010) at 
the present time, allopurinol and febuxostat are the available drugs used to obstruct 
xanthine oxidase activity and reduce serum uric acid levels. The most frequently used 
2 
drug for the treatment of chronic gout is allopurinol and it has been used for more than 
40 years clinically. Despite that, due to hypersensitivity or intolerance to the drug, or 
failure of the treatment, allopurinol cannot be used on certain patients. This is because 
of life-threatening undesirable effects of allopurinol like hypersensitivity syndrome 
which includes fever, skin rash, eosinophilia, hepatitis, and renal toxicity. These 
conditions possess mortality rate near to 20%. As stated by Lü et al. (2013) we are in 
need of finding new xanthine oxidase inhibitors with more precise effects and fewer 
side effects as compared to allopurinol and febuxostat in order to inhibit and fight gout 
and cardiovascular diseases associated with hyperuricemia. 
Natural medicines of plant origin portrayed a very notable role in human disease 
therapy and impediment for a thousand years globally (Chin et al., 2006). Balunas & 
Kinghorn (2005) stated that natural products revealed from medicinal plants contributed 
an abundance of clinically helpful medicament and are foreseen to continue being a 
fundamental role in the new medicines research. Pandanus amaryllifolius Roxb. is a 
common plant found in South East Asia and often known as pandan (Nor et al., 2008). 
In traditional medical field of South East Asia, P. amaryllifolius leaves are useful for 
body revival, fever reducing and also relieving indigestion and flatulence (Cheeptham & 
Towers, 2002). Apart from that, the leaves of P. amaryllifolius are extensively used to 
enhance flavour in assorted food dishes (Bhattacharjee et al., 2005). To the extent of our 
knowledge, currently no one has examined the effects of P. amaryllifolius on in vitro 
and in vivo xanthine oxidase inhibitory activity. For this reason, this medicinal plant 
was selected for study. The outcome of this research will be beneficial to discover novel 
xanthine oxidase inhibitor derived from natural substances as an effective therapy for 
hyperuricemia in Malaysia. 
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1.1 Research objectives 
1. To identify the phytochemical compounds in P. amaryllifolius using Thin Layer 
Chromatography (TLC), Gas Chromatography Mass Spectrometry (GC-MS) 
and Liquid Chromatography Mass Spectrometry (LC-MS). 
2. To quantify the phenolic and flavonoid content in P. amaryllifolius. 
3. To determine the antioxidant activity of P. amaryllifolius. 
4. To evaluate the xanthine oxidase inhibitory activity of P. amaryllifolius in in 
vitro and in vivo model. 
4 
CHAPTER 2: LITERATURE REVIEW 
 
2.1 Purine metabolism 
According to Ishikawa et al. (2013) purines are the constituents of nucleosides which 
are the building blocks of DNA and RNA. The nucleosides of purine such as adenosine 
and guanine, are typically utilized in order to make other crucial elements in metabolic 
system like adenosine triphosphate (ATP), guanosine-5‘-triphosphate (GTP), cyclic 
adenosine monophosphate (cAMP), nicotinamide adenine dinucleotide (NADH), and 
nicotinamide adenine dinucleotide phosphate (NADPH). The chemical structure of 
purine and its derivatives family such as adenine, guanine, isoguanine, xanthine, 
hypoxanthine, uric acid, caffeine, and theobromine are depicted in Figure 2.1. 
 
Figure 2.1: Chemical structures of purine and its derivatives, i.e., adenine, guanine, 
hypoxanthine, xanthine, theobromine, caffeine, uric acid, and isoguanine (Ishikawa et 
al., 2013) 
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In the metabolic pathway of purine catabolism, to convert two purine nucleic acids, 
adenine and guanine, to uric acid, the process needs the presence of multiple enzymes 
(Jin et al., 2012). The process comprise of various steps of reactions using different 
enzymes such as AMP deaminase, 5‘-nucleotidase, adenosine deaminase, purine 
nucleoside phosphorylase, guanine deaminase and xanthine oxidase (Ishikawa et al., 
2013).  
In the beginning, AMP (adenosine monophosphate) is converted to inosine by two 
separate steps. First, AMP in converted to IMP (inosine monophosphate) by removing 
an amino group via enzyme AMP deaminase then followed by dephosphorylation to 
form inosine using enzyme 5‘-nucleotidase; or secondly, by converting AMP to 
adenosine by removing a phosphate group via enzyme 5‘-nucleotidase followed by 
deamination reaction of adenosine to form inosine using enzyme adenosine deaminase.  
GMP (guanine monophosphate) undergo conversion to form guanosine by enzyme 
5‘-nucleotidase. The nucleosides which are the inosine and guanosine, are then 
converted to purine base hypoxanthine and guanine, respectively by enzymatic reaction 
of PNP (purine nucleoside phosphorylase). Hypoxanthine undergoes oxidation to 
become xanthine by enzyme xanthine oxidase, whereas guanine undergoes deamination 
to become xanthine by enzyme guanine deaminase. 
Xanthine is then further converted by oxidation to form uric acid via xanthine 
oxidase (Maiuolo et al., 2016). Thus, any incident of the abnormalities occur in this 
pathway increases the level of uric acid (Wong et al., 2014). The purine catabolism 
pathway is depicted in Figure 2.2. 
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Figure 2.2: Schematic diagram of the purine degradation pathway (Pacher et al., 
2006) 
 
Because molecules that contain purines are crucial for survival, vertebrates, 
including humans, have established a powerful system to generate enough purine 
nucleosides to be utilized in metabolism using materials such as glucose, glycine, and 
glutamine that are easily available in the body. Apart from that, purine nucleosides can 
also be recovered by obtaining it from the diet or from the body itself. Mammals get rid 
of the excess purine nucleosides by breaking it down in the liver and then expelled by 
the kidneys (Ishikawa et al., 2013). 
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2.1.1 Xanthine oxidase 
Xanthine oxidase exists as an active form homodimer having a molecular mass of 
approximately 290 kDa, where each of the identical monomer subunit (approximately 
145 kDa) performs in independent manner during catalytic reaction (Lin et al., 2002). 
Every subunit is made up of an N-terminal 20-kDa domain that contains two iron-sulfur 
clusters, a central 40-kDa flavin adenine dinucleotide (FAD)-binding domain and a C-
terminal 85-kDa molybdopterin-binding domain with the four redox centers positioned 
in practically linear manner. It is an important enzyme that performs catalytic reaction 
in terminal two steps of purine catabolism in humans (Borges et al., 2002).  
Xanthine oxidase appears as molybdopterin-containing flavoproteins that carry out 
the catalytic hydroxylation of hypoxanthine to xanthine, and subsequently xanthine to 
uric acid (Pacher et al., 2006). Uric acid is the final compound in the pathway (Doehner 
et al., 2016). Xanthine oxidase can be found in wide range of organs such as kidney, 
liver, lung, gut, brain, heart, and also plasma (Pacher et al., 2006). Three main organs 
that play crucial role in metabolism and excretion are kidney, liver, and lung (Borges et 
al., 2002). 
Aside from being a housekeeping enzyme, xanthine oxidase acts as rate-limiting 
enzymes in purine nucleotide degradation. It is represented by two structures which are 
xanthine oxidase (XO) and xanthine dehydrogenase (XDH) (Cantu-Medellin & Kelley, 
2013). Both xanthine oxidase and xanthine dehydrogenase presents as interconvertible 
forms of the same enzyme (Pacher et al., 2006). Xanthine oxidase favors oxygen (O2) 
whereas xanthine dehydrogenase favors NAD
+
 as electron acceptors. As a terminal 
electron acceptor, oxygen is bonded to electrons in unstable manner generating 
hydrogen peroxide (H2O2) and superoxide anion (O
-
) spontaneously. Xanthine 
dehydrogenase undergoes oxidation to form uric acid, while the electrons move through 
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Fe/S transporters to FADH2. In the process, NAD
+
 is reduced to NADH. When xanthine 
oxidase is oxidized to uric acid, the electrons are transported to FAD and O2 is 
transformed into H2O2 and O
- 
by reduction reaction (Cantu-Medellin & Kelley, 2013). 
Xanthine oxidase that comes from mammals, including humans, is produced in the form 
of dehydrogenase. However, they are easily transformed into oxidase form via oxidation 
of sulfhydryl residues or proteolysis (Pacher et al., 2006). Figure 2.3 shows the 
conversion of xanthine dehydrogenase and xanthine oxidase to uric acid. 
 
Figure 2.3: Oxidation of XDH (left) and XO (right) (Maiuolo et al., 2016) 
 
Xanthine oxidase is regarded as a key donor of free radicals that lead to in many 
pathological conditions (Mamat et al., 2014) especially during exercise (Spanou et al., 
2012). This is because the catalytic oxidation of xanthine oxidase generates superoxide 
radicals during the enzymatic process (Chu et al., 2014). Excessive reaction of xanthine 
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oxidase causes increased amount of uric acid which consequently increase the 
accumulation of uric acid in receptive tissues, and hence prompts the inflammatory 
pathways along with the release of reactive oxygen species (Pacher et al., 2006). It can 
causes oxidative damage to existing tissues that are essential in numerous pathological 
activities like cancer, aging, inflammation and atherosclerosis (Sweeney et al., 2001).  
Remarkably, the first biological system to be recognized in generating reactive 
oxygen species (ROS) is xanthine oxidase (McCord, 1968). Xanthine oxidase also 
contributes as the role of major ROS producing source in human body where ROS are 
manufactured stoichiometrically by the enzymatic reaction of xanthine oxidase 
(Doehner et al., 2016). As stated by Scott et al. (2013) the elevated level of ROS in 
human body system may exhibit broad variety of damaging effects over long-term 
periods. However, in the circumstances of the inflammatory response, xanthine oxidase 
is believed to fight the attacks of harmful pathogens by producing ROS and can act as 
the medium of innate immunity (Martin et al., 2004). 
 
2.1.2 Uric acid 
Production of uric acid is occurs predominantly in the liver and it is discarded into 
the urine by kidneys (Hayashi et al., 2000). Represented by molecular formula of 
C5H4N4O3 uric acid (7,9-dihydro-1H-purine-2,6,8(3H)-trione) is a heterocyclic organic 
compound having a molecular weight of 168 Da. Uric acid is a weak acid 
physiologically representing a pKa of 5.8 where it mainly appears as the salt of uric 
acid, urate. When the concentration of urate escalates, the production of uric acid crystal 
escalates. Normal uric acid indicator in human blood is 2.5 to 7.0 mg/dL for male and 
1.5 to 6.0 mg/dL for female. Uric acid possesses low solubility in water, where its 
average concentration in human blood is near to solubility limit (6.8 mg/dL). As the uric 
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acid quantity increases more than 6.8 mg/dL, uric acid crystals become monosodium 
urate (MSU) (Jin et al., 2012). The concentration of solubility of monosodium urate is 
dependent on diet, body weight, age, pH, and temperature (Campion et al., 1987). In the 
majority of mammals, the conversion of purine into intermediate uric acid is assisted by 
enzyme uricase in which the intermediate uric acid is then converted into a compound 
called allantoin. Allantoin is a compound that has a very high solubility. It can move 
through the bloodstream and discarded out of the body after being filtered by the 
kidneys (Ishikawa et al., 2013). On the contrary, because humans are lacking of enzyme 
uricase, we are unable to oxidize uric acid into allantoin and therefore, uric acid is 
largely discarded by kidneys everyday (Jin et al., 2012). 
Uric acid levels in blood are influenced by two aspects. First is the proportion of uric 
acid synthesis in the liver and second is the rate of uric acid discharge from the kidneys 
(Ishikawa et al., 2013). The making of uric acid and its degradation process are complex 
because many factors that control hepatic production as well as uric acid excretion of 
renal and gut are involved. The exogenous pool of purines and endogenous purine 
metabolism contribute to the production of uric acid as an end product. The exogenous 
pool differs outstandingly according to the amounts of purines obtained from the diet as 
well as amounts of purines synthesized from the proteins of animal. On the other hand, 
the sources of endogenous uric acid formation are from liver, intestines, and tissues like 
vascular endothelium, kidneys, and muscles (Chaudhary et al., 2013). Excretion of uric 
acid from kidneys possesses an outstanding impact on the level of uric acid in blood 
(Ishikawa et al., 2013). The rise of serum uric acid level give rise to the occurrence of a 
few disorder related to oxidative stress (Haidari et al., 2011). 
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2.2 XO-related diseases 
The capability of xanthine oxidase in generating ROS be the cause of increasing 
interest in the enzyme as being the starter of tissue injury in many pathological 
conditions (Bonomini et al., 2008). Constant exposure to contaminants and chemicals 
results elevated level of free radicals in the body, which are considered as the principal 
reason behind the emerge of different diseases and disorders (Cheng et al., 2003).  
Xanthine oxidase causes diverse ischemia-reperfusion injury in tissues, vascular 
injuries, and inflammation. Apart from that, its action gives an exceptional impact on 
viral infection, oxidative stress, respiratory syndrome, thermal stress, brain edema, and 
hemorrhagic shock in vivo (Naoghare et al., 2010).  
According to Boban et al. (2014) xanthine oxidase is also implicated in cellular 
aging, atherosclerosis, hypertension, and metabolic disorders. Borges et al. (2002) 
added that xanthine oxidase activity has distinctly leaded to myocardial infarction, 
diabetes, and cancer. Pacher et al. (2006) stated that mutagenesis and hepatitis are the 
diseases linked by elevated xanthine oxidase serum level. It is found that level of serum 
uric acid level is usually rose in heart failure with strong relation to heart failure severity 
according to NYHA (New York Heart Association) or the capacity of spiroergometry 
exercise (Doehner et al., 2001). Increased level of uric acid is proven in few studies to 
be a powerful and autonomous predictor of death in heart failure patients (Doehner et 
al., 2016). Song et al., (2015) stated that chronic kidney disease and cardiovascular 
disease are the outcome from xanthine oxidase activities. Nevertheless, above all, 
excessive uric acid level in the blood contributes to the development of hyperuricemia, a 
clinical complication that causes gout disease (Lü et al., 2013). 
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2.2.1 Hyperuricemia and gout 
According to Gliozzi et al. (2016) hyperuricemia and gout are pathological disorder 
distinguished by excessive making and insufficient excretion of uric acid, the terminal 
output of purine metabolism pathway discharged through the urine. It is primarily due to 
metabolic disorder on uric acid production or excretion in the body (Haidari et al., 
2008). Apart from gout, recent research showed that asymptomatic hyperuricemia is 
connected to cardiovascular diseases (Agabiti-Rosei & Grassi, 2013) as well as tumor 
lysis syndrome (TLS) and chronic kidney disease (CKD) (Edwards, 2008). Roughly 
90% of hyperuricemia occurrence is associated with damaged renal excretion (Choi & 
Ford, 2007). Edwards (2008) stated that apart from gouty arthritis, hyperuricemia is an 
exceptionally well-verified reason for kidney stones development in uric acid and acute 
kidney failure. Factors that play part in triggering hyperuricemia are insulin opposition, 
obesity, consumption of alcohol, use of diuretic, genetics, hypertension, renal 
insufficiency, and others (Yamamoto et al., 2005). 
Gout or gouty arthritis is a metabolic disorder that occurs when elevated 
concentration of uric acid present in the blood develop microscopic crystals in the joint 
after a period of time. This as a consequence, results in acute inflammatory arthritis 
(Janssens et al., 2006) generally due to xanthine oxidase over-activity in purine 
degradation (Burke et al., 2006). The accumulation of the monosodium urate crystals 
(needle shaped) in the synovial fluid of the major joints causes an utmost painful critical 
arthritis accompanied with periodic gout attacks (Rang et al., 2001) such as painful 
inflammation, swelling and erythema (Irondi et al., 2016). Two types of gout are acute 
gout and chronic gout, where chronic gout is always connected by hyperuricemia (Ling 
& Bochu, 2014). The involvement of the sudden attacks in gout frequently occurs in the 
joint at the bottom of the big toe and often happens when the body temperature is at its 
lowest degree during early hours of a day. Despite the fact that the severe strike of gout 
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is short-lived and diminish spontaneously, the effect can momentarily weaken that 
particular person and increase susceptibility of the next attacks (Becker et al., 2005). 
Lin et al. (2013) revealed that gout may lead to deformities on ocular surface for 
example vascular changes, tophi deposition, and subconjunctival transparent vesicles.  
Gout is one of the most prevalent diseases that give impact on human and its incident 
keep on growing compared to the last few decades (Sowndhararajan et al., 2012). 
According to Richette & Bardin (2010) not more than 2% of adults in industrialized 
nations are affected by gout and this ailment denoted as the most recurrent case of 
inflammatory arthritis in men. The burden of gout is increasing globally, with the 
prevalence recorded at 0.08% (Smith et al., 2014). The prevalence of gout rises with age 
in all countries where the data reaches a plateau for individuals older than 70 years old, 
meanwhile in terms of sex, men exhibited higher gout prevalence than women (Kuo et 
al., 2015). The manifestation of gout disease is due to a person‘s lifestyle and diet. 
Heavy alcohol drinks such as beer and liquor, and foods rich in nucleic acids such as 
meats and seafood impart a great influence on development of gout (Saag & Mikuls, 
2005). High consumption of fructose also reported to be one of the risk factors of gout 
(Dubchak & Falasca, 2010). Three phases for gout management are: (i) healing the 
acute attack; (ii) reducing the uric acid level to obstruct eruption of gouty arthritis and 
deposition of urate crystals in tissues; and (iii) preventive treatment to avert acute flares 
(Schlesinger, 2004). Therefore, one way to cure gout is by utilizing a compound that has 
the capability to enhance the excretion of uric acid or suppress the biosynthesis of uric 
acid (Umamaheswari et al., 2009).  
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2.3 Xanthine oxidase inhibitors 
Since xanthine oxidase is the key enzyme that fundamentally generates uric acid in 
purine catabolism, it is regarded as the most assuring goal in the therapy of 
hyperuricemia and gout (Lü et al., 2013) by acting like a mediator that can effectively 
decrease the activity of xanthine oxidase (Becker et al., 2005) and suppress uric acid 
generation (Borges et al., 2002). Allopurinol and febuxostat are the drugs that possess 
antihyperuricemia effect and able to competitively retard the activity of xanthine 
oxidase (Kumar & Azmi, 2014). Another new drug for hyperuricemia therapy is 
topiroxostat (Ohya & Shigematsu, 2014) and pegloticase (Burns & Wortmann, 2012). 
The investigation of possible inhibitors of enzyme in natural or artificial sources is a 
crucial stage to uncover potential drugs and its process of development. Apart from its 
inhibitory capability, the compounds should manifest a strong selectivity towards 
targeted enzyme so that the desired outcome can be achieved even with low dosage 
(Rodrigues et al., 2016). Figure 2.4 shows the chemical structures of allopurinol and 
febuxostat as xanthine oxidase inhibitors. 
 
Figure 2.4: Chemical structures of allopurinol and febuxostat (Song et al., 2016) 
 
 
15 
2.3.1 Allopurinol 
Allopurinol (1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) is a xanthine oxidase 
inhibitor that owns structure similar to purine (Wortmann, 2005). It is the first-line drug 
for treating hyperuricemia and its complications (Wu et al., 2015). Allopurinol acts by 
blocking xanthine oxidase activity in the final step of uric acid biosynthesis, thus 
reducing the serum urate level. Clinically, the use of allopurinol has been employed for 
more than four decades (Lü et al., 2013) and first approved by Food and Drug 
Administration (FDA) to decrease serum urate level (Emmerson, 1996). The efficacy of 
allopurinol is dose-linked and to achieve the target urate level, doses higher than the 
often used prescription (300 mg/dL) is required (Reinders et al., 2009). Allopurinol is 
the most common medication used in gout and tumor lysis syndrome (TLS) treatment. 
However due to allopurinol hypersensitivity and zero effect, zero endurance to the toxic 
effect of allopurinol, and drug-drug communication with allopurinol, refractory gout is 
initiated in patients (Mughal et al., 2010). That being the case, combining a compound 
with allopurinol, and lessens the required high dose of allopurinol for hyperuricemia or 
gout therapy conveys a desirable potential in clinical field (An et al., 2010).  
Allopurinol is notably known to possess significant undesirable effects like renal 
damage and skin reactions due to its administration (Doehner et al., 2016). Superoxide 
radicals are produced from the reaction involving allopurinol (Berry & Hare, 2004). The 
most common impacts of allopurinol are hypersensitivity response, gastrointestinal 
disturbance, and skin rash, where the reaction of hypersensitivity may reoccurring 
within months and years of taking the drug. Patients that suffer reduced renal functions, 
with constant allopurinol dosage are generally susceptible to these adverse effects 
(Pacher et al., 2006). According to Tsai & Yeh (2010) the other life-threatening effects 
of allopurinol hypersensitivity syndrome are fever, hepatitis, and eosinophilia. Other 
adverse effects of allopurinol are Toxic Epidermal Necrolysis syndrome (TENS) and 
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Stevens-Johnson syndrome (SJS) (Halevy et al., 2008). Approximately 44 cases of 
Stevens-Johnson syndrome emerged in every million new patients treated with 
allopurinol (Kim et al., 2013). These serious cutaneous adverse reactions (SCARs) of 
allopurinol usually appear in the range of three months after the treatment or increased 
dose initiation (Reinders et al., 2009). The adverse effects of allopurinol result in the 
termination of the therapy in not more that 5% patients, and analysis made by several 
studies proposed that the level of cooperation of the drug therapy with patients is only 
about half of the periods of treatment (Riedel et al., 2004). 
 
2.3.2 Febuxostat 
Febuxostat is a novel nonpurine specific inhibitor of xanthine oxidase (both oxidized 
and reduced form) which is approved by US Food and Drug Administration (FDA) in 
February 2009 to manage hyperuricemia in individuals that suffer from gout disease 
(Ernst & Fravel, 2009). Febuxostat is believed to act as a better potential alternative to 
allopurinol due to the fact that it possess the least possible effects on enzymes 
encompassed in purine metabolism pathway and it is metabolized by the oxidation 
reaction in the liver and formation of glucuronide (Becker et al., 2005). For a patient 
with hyperuricemia, febuxostat is a potentially better alternative than allopurinol 
(Tojimbara et al., 2014) and according to Ernst & Fravel (2009) febuxostat has been 
successfully used in individuals that experience intolerance towards allopurinol. Report 
findings showed that most patients have high tolerance to febuxostat (Terkeltaub, 2010). 
Ye et al. (2013) stated that febuxostat is safe to be used in patients that have mild to 
moderate renal injury.  
For the treatment of individuals with asymptomatic hyperuricemia, the use 
allopurinol and febuxostat are not advised due to the fact that they exhibit possible side 
17 
effects (Khanna et al., 2012). The adverse events that could occur from the 
administration of febuxostat are skin rash, nausea, arthralgias, and escalated liver 
enzyme. In addition, the administration of febuxostat should be partly covered by 
colchicines or NSAID (Nonsteroidal Anti-inflammatory drugs) initially because acute 
flares may arise during the beginning of the treatment (Ernst & Fravel, 2009). In 
patients with CKD (Chronic Kidney Disease) the side effect of neutropenia was 
reported due to the use of febuxostat (Kobayashi et al., 2013). Febuxostat showed 
moderate increasing risk of skin reactions in individuals with an experience of 
cutaneous adverse events with allopurinol (Bardin et al., 2016). Study by Faruque et al. 
(2013) revealed that even though febuxostat is connected to display high probability of 
getting ideal serum urate level of <6.0 mg/dL, the pooled results showed significant 
heterogeneity. Clinically, there is no verification that febuxostat is better than 
allopurinol and since febuxostat is higher in cost, they suggested that it should not be 
regularly used for individuals with chronic gout. 
 
2.3.3 Natural alternatives 
Since ancient times, plants have been extensively utilized in almost all medicinal 
therapy until the advance of synthetic drugs begins in 19
th
 century (Zheng & Wang, 
2001). A number of natural products show potent effects in reducing uric acid level, 
thereby recover hyperuricemia with hepatorenal dual regulation (Hao et al., 2016). 
Regardless of the present of drugs like allopurinol and febuxostat as xanthine oxidase 
inhibitors, allergic responses are triggered on certain patients because of these 
medications. Thus, researchers are focusing extensively on phytomedicines as xanthine 
oxidase inhibitors. For that reason, the utilization of medicinal plants becomes 
significant in the therapeutic cure of gout and other chronic diseases (Kumar & Azmi, 
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2014). These medicinal plants can undertake the role of natural gout medication, 
replacing other synthetic drugs (Azmi et al., 2012). The advantages of using herbal 
medicines in curing diseases are less side effects, notable efficiency, comparative safety, 
and less expensive to those who cannot afford to have expensive medication (Sunmonu 
& Afolayan, 2013). However, the use of medicinal plants in modern treatment is 
afflicted by their insufficiency in scientific evidence (Zhu et al., 2004). This is because 
medicinal plants were used based on the experience of old medicine system in curing 
and preventing hyperuricemia and gout (Kong et al., 2000). Zhu et al. (2004) claimed 
that natural polyphenolic compounds like flavonoids exhibited the activity of xanthine 
oxidase inhibition in the form of purified extracts. Umamaheswari et al. (2009) stated 
that the presence of phenolic and flavonoid compounds in an extract may contribute to 
xanthine oxidase inhibitory activity. Phenolic compounds are secondary metabolites that 
are usually present in plants in which they are involved in antioxidant activity and 
beneficial to defend plants from the attack of pathogens and radiation (Tiveron et al., 
2012). Countries like India, Vietnam, Philippine and north east America own few 
medicinal plants that possess xanthine oxidase inhibitory effect (Wong et al., 2014). It 
has been discovered that antioxidants obtained from plants exhibit antigout capacity. 
This is because from several in vitro studies that have been conducted, compounds like 
alkaloids (eg: piperine), phenolics (eg: caffeic acid), essential oils (eg: 
cinnamaldehyde), tannins (eg: gallic acid), flavonoids (eg: quercetin), coumarins (eg: 
fraxetin), and iridoid glucosides (eg: specioside) are likely to possess antigout potential 
by inhibiting xanthine oxidase activity (Ling & Bochu, 2014). Latest evidence showed 
that polyphenols exhibit dual effects which are inhibiting xanthine oxidase and 
scavenging free radicals. This proposes new discovery in therapeutic approach to 
diseases like hyperuricemia, oxidative stress triggered from uric acid, inflammation, and 
tissue damage (Gliozzi et al., 2014). 
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2.4 Studied plant - Pandanus amaryllifolius Roxb. 
P. amaryllifolius which is also known as ‗daun pandan‘ or ‗pandan wangi‘ belongs to 
the member of screw pine family Pandanaceae. It is a typical culinary plant distributed 
in South East Asia tropical region (Ooi et al., 2004). In countries like Malaysia, 
Thailand, Indonesia, and India, this fragrant screw pine is cultivated extensively 
(Rayaguru & Routray, 2010). According to Callmander et al., (2012) the family 
Pandanaceae world distribution includes Malaya, Borneo, Thailand, Philippines, India, 
Australia, Africa, New Guinea, Madagascar, New Caledonia, Solomon Islands, Sao 
Tomé Island (Figure 2.5). The taxonomy of P. amaryllifolius is as follow (APG III 
system 2009): 
Table 2.1: Taxonomic position of Pandanus amaryllifolius Roxb. 
Kingdom: Plantae 
Angiospearmae 
Monocots 
Order: Pandanales 
Family: Pandanaceae 
Genus: Pandanus 
Species: Pandanus amaryllifolius Roxb. 
 
 
Figure 2.5: World distribution of family Pandanaceae (Nadaf & Zanan, 2012) 
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William Roxburgh is a botanist and Scottish surgeon that described P. amaryllifolius 
(Nadaf & Zanan, 2012). Genus Pandanus consists of roughly 700 species widespread in 
both tropical and sub-tropical areas (Tan et al., 2012). Plants from genus Pandanus 
appear as evergreen trees or shrubs that are palm-like (Bhattacharjee et al., 2005). The 
leaves of pandan are green in colour, has narrow and strap shape appearance and 
spirally arranged at apex of stems (Figure 2.6) (Peter, 2012). The blades of P. 
amaryllifolius leaves usually 25–75 cm in length, 2–5 cm in width (small form) and 
150–220 cm in length, 7–9 cm in width (large form), seldom with 1–3 little stout 
prickles on midrib adjacent to the base (Wakte et al., 2009). The stem of P. 
amaryllifolius is slender roughly 2–5 cm in thickness. Its height can extend up to 4.5 m, 
if appropriate support is given and factors that lead to prostration is absent. Two 
categories of height are up to 1.6 m (small form) and up to 4.5 m (large form) (Wakte et 
al., 2007). The growth forms of P. amaryllifolius are depicted in Figure 2.7. 
 
Figure 2.6: Pandanus amaryllifolius Roxb. (Zanan et al., 2016) 
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Figure 2.7: Distinct small and large forms of P. amaryllifolius (Wakte et al., 2009) 
 
P. amaryllifolius is the sole species of family Pandanaceae that owns fragrant leaves. 
The main compound responsible in representing aromatic feature in P. amaryllifolius is 
2-acetyl-1-pyrroline (2AP) (Yahya et al., 2010). Quantitatively, 2AP present in this 
plant possesses the highest amount among the plant kingdom. This compound is the 
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similar to the ones present in aromatic rice like Jasmine and Basmati rice. For that 
reason, pandan leaves are used in cooking plain unscented rice to mimic aromatic rice 
varieties which are a lot pricey, as a substitute (Ravindran & Balachandran, 2005). 
Essential oils present in pandan leaves convey tenfold more flavor than aromatic rice 
(Rayaguru & Routray, 2010). Pandan leaves are used in large-scale in cooking because 
of its natural food dye and its scent (Han et al., 2014). Abundant chlorophyll present in 
the leaves provides green colour to foods and drinks (Zanan et al., 2016). The extracts 
of pandan leaves are used as an essence in bakery (Bhattacharjee et al., 2005) as a 
substitute to vanilla essence (Wyk, 2005). The powdered form of green pandan leaves is 
safe to use as food additive (Porrarud & Pranee, 2010). Occasionally, the leaves are put 
into frying oils in order to transmit its flavor to the fried food (Nor et al., 2008). At 
times, pandan leaves are added in cold drinks made from unripe coconut water as well 
as to custards and sweetened puddings made from sticky glutinous rice (Bhattacharjee et 
al., 2005). In Malaysia, pandan leaves are used to make coconut jam, candies, ice 
cream, and desserts (Ghasemzadeh & Jaafar, 2014). It can also be used in flavouring 
meat and vegetables or blend with sauces to enhance the taste (Rayaguru & Routray, 
2010). According to Ravindran & Balachandran (2005) the famous breakfast menu in 
Malaysia, ‗Nasi Lemak‘ is a traditional dish made by mixing the rice with ‗santan‘ 
(coconut milk) and pandan leaves that are soaked during the cooking process. 
Apart from its culinary importance, pandan is utilized as ornamental plants as well as 
grown in kitchen garden due to its ability to live in wild condition (Rayaguru & 
Routray, 2010). Pandan leaves can also be implemented as a pest management agent 
because it is natural and environmentally friendly, for instance, taxi drivers in Malaysia 
and Singapore are said to put P. amaryllifolius leaves in their taxi to fend off 
cockroaches. P. amaryllifolius possess secondary value in intensifying visual and 
olfactory pleasure to humans. In Malaysia, pandan leaves is used traditionally as 
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medicinal bath and hair wash to mothers after giving birth. ‗Potpourri‘ which is a mix of 
chopped pandan leaves with the petals of several sweet-smelling flowers is used in 
traditional celebrations in Malaysia. In Philippines, pandan leaves are used to prepare a 
lotion along with vinegar and ash in healing measles, leprosy, sore throat, and as 
laxatives (Samy et al., 2005). 
Apart from being utilized in perfume-making industry, P. amaryllifolius possesses 
antidiabetic, cardio-tonic, and diuretic (Wakte et al., 2010) as well as antispasmodic, 
and stimulant properties (Quisumbing, 1978) in medical field. P. amaryllifolius leaves 
are used in refreshing the body, curing fever, and healing indigestion (Cheeptham & 
Towers, 2002). It is also used to heal problems related to thyroid (Jong & Chau, 1998). 
Pandan leaves are immersed in coconut oil for a few days and later the oil is used to 
heal rheumatism. Leaves infusion is obtained internally to relieve restlessness. In 
Thailand, P. amaryllifolius is used traditionally to combat diabetes (Ravindran & 
Balachandran, 2005). According to Ooi et al. (2004) unglycosylated pandamin protein 
is present in the pandan leaves which express antiviral mechanism against influenza 
virus and human virus, herpes simplex virus type-1. Ghasemzadeh & Jaafar (2014) 
stated that P. amaryllifolius shows antioxidant bioactivities. Study made by Nor et al. 
(2008) reported that ethanol extract of P. amaryllifolius grown in Malaysia displayed an 
exceptional heat-stable antioxidant feature. The content of P. amaryllifolius includes 
quercetin (Miean & Mohamed, 2001), alkaloids such as Pandanusine A (Cheng et al., 
2017), fatty acids and esters (Zainuddin, 2004), tocopherols, tocotrienols, and 
carotenoids (Lee et al., 2004) and non-specific lipid transfer proteins (Ooi et al., 2006). 
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2.4.1 Phytochemical study on P. amaryllifolius 
Medicinal plants possess phytochemical compounds which are crucial in exerting 
health goodness or improving state of ailment. However, numerous phytochemicals are 
still unidentified (Boyer & Liu, 2004). Study by Ghasemzadeh & Jaafar (2013) showed 
that P. amaryllifolius leaves have good bioactive compounds such as phenolic acids 
(gallic acid) and flavonoids (catechin, kaempferol and naringin). These bioactive 
compounds showed synergistic ability in obstructing breast cancer cell proliferation and 
could be the prospective natural food additive. Research by Wakte et al. (2012) showed 
that out of 31 volatiles, five major volatile compounds detected in P. amaryllifolius are 
2AP, nonanal, phytol, 2-hexenal, 2,6-nonadienal and hexanal. Dominant components of 
essential oils obtained from the leaves are phytol, squalene, pentadecanal, 
pentadecanoic acid, 3,7,11,15-tetramethyl-2-hexadecen-1-ol, and phytone (Chen & Ge, 
2014). Main carotenoids detected in P. amaryllifolius leaves are β-carotene and lutein. 
Together with carotenoids precursors which are α-carotene and β-carotene, three 
norisoprenoids discovered are α-ionone, β-ionone, and β-cyclocitral (Ningrum et al., 
2015). Study by Cheng et al. (2017) revealed seven latest alkaloids from P. 
amaryllifolius ethanolic extract which are pandanusine A (1), pandanusine B (2), 
pandalizine C (3), pandalizine D (4), pandalizine E (5), norpandamarilactonine C (6), 
and norpandamarilactonine D (7) (Figure 2.8). 
 
Figure 2.8: Structures of new alkaloids (Cheng et al., 2017) 
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2.5 Antioxidant 
Antioxidant is a substrate that prevents or delays the oxidation of another substrate. It 
often exists in a very low concentration (Halliwell & Gutteridge, 1989). Being the 
fundamental role in keeping the body healthy, the main sources of naturally existing 
antioxidants are commonly derived from vegetables, fruits, and whole grains. Vitamin 
C, Vitamin E, phenolic acids, carotenes, phytate and phytoestrogens from plants have a 
potential to decrease risk of diseases. In normal diet, almost all antioxidants are 
obtained from plants where the antioxidant compounds are categorized into assorted 
classes representing an assortment of physical and chemical properties (Prakash, 2001). 
Consumption of vegetables and fruits is linked to low chance of cancer and 
cardiovascular diseases (Cazzi et al., 1997). 
The amount of phenolic compounds in plants is ubiquitous. They appear as a crucial 
contributor of colour and flavour in numerous fruits and vegetables. They exist as C15 
compounds with two phenolic rings linked by a 3-carbon unit. They are grouped based 
on the different substituent present on the rings and the level of ring saturation. Often, to 
raise their solubility in water, they are chained to sugar moiety (Lin et al., 2001). 
Compounds like gallates have strong antioxidant capability whereas compounds like 
mono-phenols are weak antioxidants (Prakash, 2001). Phenolic compounds possess 
antimicrobial, anti-inflammatory, antithrombotic, antiallergenic, antiartherogenic, 
vasodilatory and cardioprotective effects (Alpinar et al., 2009). Because of its 
conjugated rings and hydroxyl groups, plenty of phenolic compounds are able to 
potentially function as antioxidants in oxidative reaction by stabilizing or scavenging 
free radicals better than vitamin C and vitamin E (Seyoum et al., 2003). According to 
Nijveldt et al. (2001) polyphenols play essential part in redox reaction that result in free 
radical neutralization, oxygen relieve, and peroxides decomposition. 
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Free radicals are continuously generated because the body response towards internal 
and external impulse (Matés et al., 1999). These radicals, in low quantity, play crucial 
role in controlling growth, signaling transducers, and being the members of immune 
system (Atmani et al., 2009). In spite of that, elevated free radicals level results in 
oxidative stress which as a consequence, gives rise to the emerge of diseases like 
ageing, cancer, arteriosclerosis, and neurodegenerative diseases (de Oliveira et al., 
2009). Even with the available of synthetic drugs which are much stable and potent, 
there is limitation for the usage of the drugs because of potential side effects that could 
occur from its activity (Pokorný, 2007). Antioxidants possess high effectiveness in 
scavenging free radicals and able to extinguish reactive oxygen species by the means of 
scavenging radicals that are about to appear, interfering chain reactions, and attachment 
of metal ions (Shah et al., 2014). The synergistic interaction of antioxidants shows 
moderate effects in preventing the oxidative damage of body cells (Karou et al., 2005). 
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CHAPTER 3: MATERIALS AND METHODS 
 
3.1 Plant sample 
1.2 kg of fresh Pandanus amaryllifolius Roxb. plants were collected from Institute of 
Biological Sciences garden, University of Malaya, Kuala Lumpur in March 2015 and 
authenticated by plant taxonomist Professor Dr. Ong Hean Chooi from Institute of 
Biological Sciences, University of Malaya. A voucher specimen of P. amaryllifolius 
with voucher no.: KLU 49087 was deposited in the Herbarium of University of Malaya, 
Kuala Lumpur. All parts of the plants including the roots were rinsed and air-dried at 
room temperature for approximately three weeks until completely dried. The 417 g of 
dried samples were then ground into fine powder using a blender. 
 
3.2 Chemicals and reagents 
Bismuth nitrate, potassium iodide, vanillin, sodium carbonate, sodium nitrite, sodium 
acetate, sodium hydroxide, sodium chloride, aluminum chloride, ferrous sulfate, ferric 
chloride, ferrous chloride, monopotassium phosphate, dipotassium phosphate, gallic 
acid, quercetin, ascorbic acid, hexane, petroleum ether, chloroform, methanol, ethanol, 
acetone, and glacial acetic acid, were purchased from Chemolab Supplier (Malaysia). 
Ethylenediaminetetraacetic acid disodium salt dehydrate, DMSO, hydrochloric acid, 
and sulphuric acid were purchased from Merck Chemical Co. (Malaysia). DPPH, TPTZ, 
ferrozine, xanthine, xanthine oxidase (source: bovine milk), allopurinol, oxonic acid 
potassium salt, ρ-anisaldehyde, Folin-Ciocalteu reagent, and hydrogen peroxide solution 
were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 
28 
3.3 Instruments 
Perkin Elmer Clarus 600 Turbo Mass GC-MS (Perkin Elmer, USA), Agilent 6550 
iFunnel Q-TOF LC/MS (Agilent Technologies, USA) with C18 column (2.1 mm × 100 
mm, 1.8 m), UV-vis spectrophotometer-1700 (Shimadzu, Japan), and microplate 
reader (Tecan Sunrise, Austria). 
 
3.4 Preparation of plant extracts 
The extraction of phytochemical compounds in P. amaryllifolius was carried out by 
soaking 25 g dried powder in hexane, petroleum ether, chloroform, methanol, and 
distilled water respectively with the ratio of 1:10 (1 g of powder per 10 mL of solvent). 
The mixture was kept in water bath at 40C for 8 hours in a closed system sealed with 
parafilm, occasionally shaken. The mixture was then filtered with filter paper. The 
filtered mixture was concentrated by rotary evaporator under reduced pressure at 40C 
to maintain phytochemical compounds from being destroyed. The crude water extract 
was obtained through freeze-drying method. The crude extracts; P. amaryllifolius 
hexane extract (PA-H), P. amaryllifolius petroleum ether extract (PA-PE), P. 
amaryllifolius chloroform extract (PA-C), P. amaryllifolius methanol extract (PA-M), 
and P. amaryllifolius water extract (PA-W) were kept in airtight container until further 
used.  
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3.5 Identification of the phytochemical compounds 
3.5.1 Thin layer chromatography (TLC) 
Thin layer chromatography was conducted to detect chemical compounds present in 
P. amaryllifolius extracts. Firstly, developing chamber was constructed by adding 
solvent system into the chamber where the depth should not exceed 0.5 cm. TLC was 
performed on silica gel, 60 F254 aluminium backed plates (size 8 cm × 2 cm) by placing 
the extract as a band on the plate using capillary tube. PA-H, PA-C, and PA-M were 
separated using solvent hexane: acetone (7:3), PA-PE was separated using solvent 
hexane: acetone (8:2), and PA-W was separated using chloroform: methanol (1:9). 
Plates with the extracts were placed inside the developing chamber and separation was 
developed. Then, the plates were dried and subjected to UV light at 254 nm and sprayed 
with Dragendroff‘s, vanillin-sulphuric acid and anisaldehyde-sulphuric acid reagents to 
detect the phytochemicals. Retention factor (Rf) value for each detected compound was 
calculated and recorded. Rf value is the ratio between the distance moved by the sample 
and the distance moved by the solvent. It is used to explain sample characteristics. 
 
Figure 3.1: Determination of Rf value on TLC plate (Millar, 2012) 
Retention factor (R    value 
Distance travelled by sample (a) cm
Distance travelled by solvent ( ) cm
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3.5.2 TLC spray reagent 
 Dragendroff’s reagent (a)
The application of Dragendroff‘s reagent on TLC chromatograms is to detect the 
presence of alkaloids in the sample. The spray reagent was prepared by preparing 
solution A (0.85 g of bismuth nitrate dissolved in 10 mL of glacial acetic acid and 40 
mL of distilled water) and solution B (8 g of potassium iodide dissolved in 30 mL of 
distilled water). After that, 25 mL of solution A, 25 mL of solution B, 100 mL of glacial 
acetic acid, and 500 mL of distilled water were mixed to make the spray reagent. 
Dragendroff‘s reagent is stable and can be refrigerated for a few weeks. The presence of 
alkaloids was detected by observing orange spot on the TLC plates. 
 Vanillin-sulphuric acid reagent (b)
Vanillin-sulphuric acid reagent was used to detect the presence of terpenoids and 
phenols in the sample. The spray reagent was made by adding 1 g of vanillin into 1 mL 
of concentrated sulphuric acid. The solution was then mixed with 100 mL of ethanol. 
The TLC plates were then sprayed with the vanillin-sulphuric acid reagent and heated 
on a hot plate for about 5–10 minutes at 100C until the colour developed. The presence 
of terpenoids and phenols were detected by observing purple (terpenoids) and green 
(phenols) spot on the TLC plates. 
 Anisaldehyde-sulphuric acid reagent (c)
Anisaldehyde-sulphuric acid reagent is able to detect the presence of phenolic 
compounds in the sample. It is prepared by mixing 0.5 mL of anisaldehyde, 10 mL of 
glacial acetic acid, 5 mL of concentrated sulphuric acid, and 85 mL of methanol 
together. The plates were then sprayed with the reagent and heated for 5–10 minutes on 
a hot plate at 100C. The presence of phenols was detected by observing violet, blue, 
red, grey or green colour. Green colour represents flavonoids. 
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3.5.3 Gas chromatography mass spectrometry (GC-MS) 
Crude PA-W and PA-M were subjected to GC-MS analyses. Out of five extracts 
available, only PA-W and PA-M were suitable to be used in specific column in GC-MS 
machine. The crude P. amaryllifolius extracts were sent to Institute of Systems Biology 
(INBIOSIS), Universiti Kebangsaan Malaysia (UKM), Selangor for analysis. Derivation 
of sample was conducted based on method by Azizan et al. (2012) using 40 L of 20 
mg/mL O-methoxyamine hydrochloride solution in anhydrous pyridine to the dried 
extracts. After the mixture was mixed vigorously, it underwent the incubation period of 
30 minutes at 60°C in a heating block. Afterward, 40 L of N-methyl-N-
(trimethylsilyl)- trifluoroacetamide (MSTFA) was added. The extracts were further 
incubated for 60 minutes at 60C. PA-W and PA-M were analyzed using Perkin Elmer 
Clarus 600 Turbo Mass GC-MS (Perkin Elmer, USA) coupled to quadrupole type MS 
operated at 70 eV. The putative identification was carried out by comparing mass 
spectral library with National Institute of Standards and Technology (NIST) library 
(2008). 1 L aliquot was injected into Elite 5MS (5% phenyl 95% 
dimethylpolysiloxane, 30 m × 0.25 mm ID × 0.25 µm) column. The flow rate of helium 
carrier gas was 1 mL/min. The initial oven temperature was set to 70C and was raised 
at 1C/min to 76C and then at 6C/min to 300C. The total run time was 50.33 
minutes. The full scan mode was acquired at a mass range of 50-500 m/z, with a solvent 
delay of 7 minutes. The injection and ion source (EI) temperature were adjusted to 
250C and 200C respectively. Samples were injected in ratio mode (50:1). 
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3.5.4 Liquid chromatography mass spectrometry (LC-MS) 
PA-W was subjected to LC-MS analyses. This is because out of five extracts 
available, PA-W showed the most positive result in antioxidant assays and xanthine 
oxidase inhibitory assay. The sample was prepared by diluting crude PA-W with HPLC 
grade water into 10 ppm concentration. The sample was then sent to INFRA Analytical 
Laboratory, University of Malaya, Kuala Lumpur for analysis. The phytochemical 
compounds of P. amaryllifolius were detected according to the method described by 
Kolniak-Ostek & Oszmiański (2015) with slight modification. The chromatographic 
separations of were carried out using LC-MS 6550 iFunnel Q-TOF System with C18 
column (2.1 mm × 100 mm, 1.8 m) at 30C. 10 L of sample was injected with the 
flow rate of 0.1 mL/min. The electrospray ionization (ESI) source was operating in 
negative mode. The mobile phase comprised of solvent A (0.1% formic acid, v/v) and 
solvent B (100% acetonitrile). A binary gradient of solvent A and solvent B was as 
follows: 99% solvent A (0–1 min), and then a linear gradient was used for 12 min, 
reducing solvent A to 0%; from 12.5 to 13.5 min, the gradient went back to the initial 
composition (99% solvent A), and then it was held constant to re-equilibrate the 
column. 
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3.6 Quantification of phenolic and flavonoid 
3.6.1 Total phenolic content (TPC) 
Folin-Ciocalteu‘s reagent was used to determine the total phenol content of P. 
amaryllifolius extracts using the method by Ablat et al. (2014) with a slight 
modification. Folin-Ciocalteu reagent was diluted 10-fold with distilled water. In a 96-
well microplate, 20 L extract was mixed with 100 L of Folin-Ciocalteu reagent and 
incubated for five minutes. Next, 75 L of sodium carbonate solution was added and the 
microplate was allowed to incubate in darkness for two hours at room temperature. 
After two hours, the absorbance was measured at 740 nm using a microplate reader 
(Tecan Sunrise, Austria). Gallic acid (concentration range: 0.0625–1.0 mM) was used as 
a standard to construct a linear regression line and the blank was water. The results were 
expressed as mg gallic acid equivalent (mg GAE)/g of dry extract. 
 
3.6.2 Total flavonoid content (TFC) 
Total flavonoid contents of P. amaryllifolius extracts were determined according to 
the method by Ablat et al. (2014). 50 L of each extracts was added into a 96-well 
microplate along with 15 L of 5% sodium nitrite solution and 70 L of distilled water. 
After mixing the solution well, it was incubated for five minutes at room temperature. 
Next, 15 L of 10% aluminum chloride solution was added and the solution was 
incubated for six minutes. Lastly, 100 L of 1 M sodium hydroxide solution was added. 
The absorbance was measured at 510 nm with a microplate reader (Tecan Sunrise, 
Austria). Quercetin (concentration range: 0.2–1.0 mM) was used for standard 
calibration curve. The total flavonoid contents were evaluated according to the linear 
regression between standard solution and absorbance at 510 nm. The results were 
estimated as mg quercetin equivalent (mg QE)/g of dry extract. 
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3.7 Antioxidant activity 
3.7.1 DPPH radical scavenging activity 
The DPPH radical scavenging activity of P. amaryllifolius extracts was assessed 
according to the method depicted by Ablat et al. (2014) with several modifications. 
First, extracts (40 L) at different concentrations (10–240 g/mL) were added into a 96-
well microplate. Then, 200 L of 50 𝜇M DPPH solution in ethanol was added and the 
mixture was instantly mixed and shaken. The microplate was allowed to incubate in the 
darkness for 15 minutes at room temperature. Absorbance was measured at 517 nm 
using a microplate reader (Tecan Sunrise, Austria). Ascorbic acid (concentration range: 
10–240 g/mL) was used as a standard and the control was ethanol. The percent 
inhibition of DPPH radical was calculated using the formula: 
DPPH radical scavenging activity ( )   
Acontrol   Asample or standard
Acontrol
 100 
The concentration of extracts needed in scavenging 50% of DPPH radical (IC50) was 
determined from the graph plotted against the percentage of inhibition and contrasted 
with the standard. The entire tests were carried out in triplicate and the results were 
expressed in g/mL. 
 
3.7.2 Ferric reducing antioxidant power (FRAP) assay 
The FRAP assay was performed according to the method by Ablat et al. (2014) with 
a few modification. 20 L of P. amaryllifolius extracts in ethanol were added into 96-
well microplate. Then, 200 L of FRAP reagent which is prepared fresh was added into 
each well containing the extracts. FRAP reagent was made by mixing 5 mL of 20 mM 
FeCl3, 5 mL of 10 mM TPTZ in 40 mM HCl, and 50 mL of 0.3 M acetate buffer (pH 
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3.6). The mixture was incubated for eight minutes in to form the TPTZ-Fe
2+
 complex. 
Absorbance was recorded at 595 nm using a microplate reader (Tecan Sunrise, Austria). 
The standard was ferrous sulfate (concentration range: 0.125–1.0 mM) and the blank 
was ethanol. The FRAP value was determined from ferrous sulfate standard curve, and 
the results were expressed as mmol Fe
2+
/g of dry extract. 
 
3.7.3 Metal chelating activity 
The ability of P. amaryllifolius extracts to chelate ferrous ion was measured 
according to the method described by Ablat et al. (2014) with slight modification. The 
test was initiated by mixing 100 L of extracts of different concentrations (10–160 
g/mL), 10 L of 2 mM FeCl2, and 120 L of distilled water together in a 96-well 
microplate. To start the reaction, 20 L of 5 mM ferrozine was added into the mixture. 
After the incubation period of 20 minutes at room temperature, the absorbance was 
recorded at 562 nm. EDTA-Na2 (concentration range: 5–160 g/mL) was used as the 
standard and the control was ethanol (100 L). The blank did not include the ferrozine 
but 20 L of distilled water instead. Chelating activity was calculated relative to the 
control using the following formula: 
Ferrous ion chelating activity ( )   
Acontrol   Asample or standard
Acontrol
 100 
The concentration of extracts needed in chelating 50% of Fe
2+
 ion (IC50) was 
determined from the graph plotted against the percentage of inhibition and contrasted 
with the standard. The entire tests were carried out in triplicate and the results were 
expressed in g/mL. 
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3.7.4 Hydrogen peroxide scavenging activity 
The P. amaryllifolius extracts scavenging ability of H2O2 molecules was assessed 
based on the method described by Khan et al. (2012) with a slight modification. First, 
0.1 mL of extracts in ethanol (concentration range: 10–320 g/mL) were added into the 
test tubes followed by the addition of 0.3 mL of 50 mM phosphate buffer (pH 7.4) to 
make the volume of 0.4 mL. After that, 0.6 mL of 2 mM hydrogen peroxide solution 
was added and the tubes were vortexed. The hydrogen peroxide solution was prepared 
in the 50 mM phosphate buffer (pH 7.4). After 10 minutes, the absorbance of hydrogen 
peroxide was then measured at 230 nm against the blank using UV-vis 
spectrophotometer-1700 (Shimadzu, Kyoto, Japan). Ascorbic acid (concentration range: 
10–320 g/mL) was used as a standard. The blank was 50 mM phosphate buffer without 
hydrogen peroxide. The percentage inhibition of hydrogen peroxide was calculated by 
the following equation: 
Hydrogen peroxide scavenging activity ( )   
Acontrol   Asample or standard
Acontrol
 100 
The concentration of extracts needed in chelating 50% of hydrogen peroxide (IC50) 
was determined from the graph plotted against the percentage of inhibition and 
contrasted with the standard. The entire tests were carried out in triplicate and the 
results were expressed in g/mL. 
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3.8 In vitro xanthine oxidase inhibitory activity 
In vitro xanthine oxidase inhibitory activity was conducted on P. amaryllifolius 
extracts aerobically using the method by Azmi et al. (2012) with several modifications. 
100 L of extracts (concentration range: 6.25–100 g/mL), 300 L of 50 mM 
phosphate buffer (pH 7.5), and 100 L of xanthine oxidase solution (0.1 units/mL in 50 
mM phosphate buffer, pH 7.5) were added into a test tube. The enzyme solution was 
prepared fresh. The mixture was then incubated for 15 minutes at 37C. The reaction 
was initiated after the addition of 200 L of 0.15 mM xanthine solution in the same 
buffer, and incubated again for 30 minutes at 37C. To stop the reaction, 200 L of 0.5 
M HCl was added. The absorbance was determined at 295 nm with UV-vis 
spectrophotometer-1700 (Shimadzu, Japan). Allopurinol (concentration range: 6.25–100 
g/mL) was the positive control. The preparation of blank was the same as the sample 
and standard. But the xanthine oxidase solution was substituted with the phosphate 
buffer. The control was 100 L of DMSO. The inhibitory activity was calculated by the 
following equation: 
Xanthine oxidase inhibition ( )   
Acontrol   Asample or standard
Acontrol
 100 
The concentration of extracts needed to inhibit 50% of xanthine oxidase (IC50) was 
determined from the graph plotted against the percentage of inhibition and contrasted 
with the standard. The entire tests were carried out in triplicate and the results were 
expressed in g/mL. 
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3.9 In vivo xanthine oxidase inhibitory activity 
3.9.1 Acute toxicity test 
6–7 weeks old Spraque Dawley rats were kept in their cages in the animal house for 
two weeks for adaptation to the standard laboratory conditions. A total of six rats (three 
male, three female) were used to receive a single oral dose (2000 mg/kg) of PA-W 
prepared using distilled water as vehicle. The rats were kept over-night fasting prior to 
extract administration. The next day, the weights of the rats were recorded and the 
extract was administered via oral gavage. After extracts administration, food but not 
water was withheld for further 3–4 hours. Observation was performed to individual rat 
during the first 24 hours with extra attention to the first 4 hours. For the next 14 days, 
they were observed daily. The signs of toxicity to be detected include change in fur and 
skin, membranes of eyes and mucous, as well as respiratory, circulatory, nervous 
system, and somatomotor activity and behaviour pattern. Individual weights of the rats 
were recorded at the day of dosing, in weekly periods and at the day of execution. 
Mortality occurrence was determined over a period of two weeks. If the rats were found 
to be in a moribund state and exhibiting serious pain or undergoing signs of very bad 
distress, they should be humanely terminated. The number of dead and surviving 
animals determines the next dose to be administered (OECD 423). 
 
3.9.2 Experimental animals 
Healthy Sprague Dawley (SD) male rats (6–7 weeks old, 150–130 g) were used in 
hypouricemic activity experiment. The rats were purchased from University of Malaya 
Animal House. 36 male rats were housed in their cages for two weeks prior to dosing to 
allow for acclimatization to the laboratory condition according to OECD 423 guidelines. 
They were maintained under standard laboratory conditions throughout experiment with 
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the sequence of lighting being 12 hours light and 12 hours dark, under room 
temperature (37ºC). Conventional rat pellet diet and unlimited supply of tap water were 
used for feeding. The protocol used in this experiment fulfilled the ethical code 
sanctioned by the Faculty of Medicine Institutional Animal Care and Use Committee 
(FOM IACUC), University of Malaya (Ethic no: 2015-180908/IBS/R/NAAS). 
 
3.9.3 Animal experimental design 
 Preparation of the hyperuricemic rat model (a)
Hyperuricemic rat model was assigned to this experiment by intraperitoneal (i.p.) 
injection of the uricase inhibitor, oxonic acid potassium salt (280 mg/kg single dose) 
according to the method by Yonetani et al. (1980). The oxonic acid potassium salt 
solution was prepared by suspending it in 0.9% sodium chloride (NaCl) solution. 
 Hypouricemic activity study (b)
Hypouricemic efficacy of PA-W was investigated using the method described by 
Umamaheswari et al. (2007) with a few modifications. In this experiment, 36 male rats 
were divided into six groups (n = 6). Group I was normal control group that received 
0.5% CMC solution orally. Group II only received high dose PA-W (1000 mg/kg) via 
oral gavage. Group III was the hyperuricemic control that intraperitoneally administered 
with oxonic acid potassium salt (280 mg/kg, i.p.). Rats of group IV and V received high 
dose (1000 mg/kg) and low dose (500 mg/kg) of PA-W by oral gavage, respectively. 
Group VI was given oral treatment of allopurinol (10 mg/kg body weight). Table 3.1 
summarized the experimental conditions. PA-W was dissolved in vehicle distilled water 
while allopurinol was dissolved in 0.5% CMC solution. One hour prior to extracts and 
allopurinol administration, hyperuricemic rats in groups III, IV, V, and VI were injected 
with oxonic acid potassium salt (280 mg/kg, i.p.) to elevate the serum uric acid level. 
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One hour after extract and allopurinol administration, small blood samples were 
collected by tail prick to measure serum urate level using Multi Sure Uric Acid Meter 
purchased from ApexBio (Taiwan) and the results were expressed as mg/dL. Right after 
the tail prick, all the rats were executed and whole blood samples were collected 
through intracardiac puncture where the blood was allowed to clot and serum separated. 
The xanthine oxidase activity of the collected serum was determined using Xanthine 
Oxidase Activity Assay Kit purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
the results were expressed as milliunit/mL. 
Table 3.1: Treatment groups 
Group Condition Treatment 
1 Normal rats Control 
2 Normal rats High dose of PA-W  [1000 mg/kg] 
3 Hyperuricemic rats Control 
4 Hyperuricemic rats High dose of PA-W [1000 mg/kg] 
5 Hyperuricemic rats Low dose of PA-W [500 mg/kg] 
6 Hyperuricemic rats Allopurinol [10 mg/kg] 
 
 
3.10 Statistical analysis 
The data values were represented as mean ± SEM (standard error of mean) for three 
replicates. Data were analyzed using one-way ANOVA followed by Dunnett‘s test for 
multiple group comparison. The statistical significance was at P < 0.001. The 
correlation between TPC, TFC, and antioxidant activities were assessed using Pearson 
correlation test (P < 0.01 and P < 0.05). 
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CHAPTER 4: RESULTS 
 
4.1 Preparation of plant extracts 
Dried Pandanus amaryllifolius Roxb. powder was extracted using five different 
solvents. P. amaryllifolius hexane extract (PA-H), petroleum ether extract (PA-PE), 
chloroform extract (PA-C), and methanol extract (PA-M) were obtained under reduced 
pressure via rotary evaporator whereas P. amaryllifolius water extract (PA-W) was 
obtained by freeze-drying method. The yield of the extracts is depicted in Table 4.1. 
Results obtained from this experiment showed that PA-W in dark brown gives the 
highest yield of 12.72% (3.18 g), followed by dark green coloured PA-M with the yield 
of 9.04% (2.26 g). From 25 g of dried weight of P. amaryllifolius powder, PA-H, PA-
PE, and PA-C displayed 0.22% (0.054 g), 0.07% (0.017 g), and 0.36% (0.089 g) yield 
of extract respectively. 
Table 4.1: Yields of P. amaryllifolius extracts in different solvents 
Extracts Dry weight 
(g) 
Crude extract 
(g) 
Yield crude 
extract (%) 
Colour of 
crude extract 
PA-H 25 0.054 0.22 Dark green 
PA-PE 25 0.017 0.07 Dark green 
PA-C 25 0.089 0.36 Dark green 
PA-M 25 2.260 9.04 Dark green 
PA-W 25 3.180 12.72 Dark brown 
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4.2 Identification of the phytochemical compounds 
4.2.1 Thin layer chromatography (TLC) 
The detection of phytochemical compounds was discovered by TLC analysis with 
different detection reagents. The first step in this analysis was developing appropriate 
mobile systems of solvents with different polarity can provide the best separation for 
each extracts. As a result, three solvent systems (hexane-acetone, 7:3; hexane-acetone, 
8:2; chloroform-methanol, 1:9) were selected and used to separate these compounds. In 
this experiment, chlorophylls, flavonoids, phenols, terpenoids, and xanthophylls were 
detected in PA-H (Table 4.2). Chlorophylls, flavonoids, terpenoids, and xanthophylls 
were detected in PA-PE (Table 4.3). Chlorophylls, phenols, and terpenoids were 
detected in PA-C and PA-M (Table 4.4 and 4.5). Phenols and terpenoids were detected 
in PA-W (Table 4.6). 
The colour results strongly suggest that terpenoids were present in all five extracts 
after the bands on TLC plates turned to purple colour when sprayed with Vanillin-
H2SO4 reagent. The detection of chlorophylls was observed when bands turned into 
green colour in visible light. Chlorophylls were present in all extracts except for PA-W. 
Xanthophylls were found only in PA-H, PA-PE, and PA-C. Flavonoid turned bands into 
green colour after sprayed with anisaldehyde-sulphuric acid reagent. It was detected in 
PA-H and PA-PE but not detected in PA-C, PA-M, and PA-W possibly because they 
were present in very low concentrations. The TLC results showed that phenols were 
detected in all extracts except for PA-PE. The purple bands appeared after reacted with 
anisaldehyde-sulphuric acid reagent indicating the presence of phenolic compounds.
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Table 4.2: TLC profile of PA-H in mobile system hexane:acetone (7:3) 
Labelled 
compound 
Rf value Colour observation Tentative ID 
of phytochemical Visible light UV 
light 
Detection with reagent 
Dragendorff Vanillin-H2SO4 ρ-anisaldehyde 
H1 0.44 yellow (++) yellow (++) - - - xanthophyll 
H2 0.51 green (+) green (+) - - purple (+) phenol 
H3 0.56 green (++) green (++) - - green (++) flavonoid 
H4 0.61 - - - purple (+++) - terpenoid 
H5 0.64 green (+++) green (+++) - - - chlorophyll 
H6 0.71 - - - purple (+++) - terpenoid 
H7 0.86 - - - purple (++) - terpenoid 
H8 0.91 - - - purple (+++) - terpenoid 
 
Indication of colour intensity: Weak (+), Medium (++), Strong (+++), No colour observed (-) 
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Table 4.3: TLC profile of PA-PE in mobile system hexane:acetone (8:2) 
Labelled 
compound 
Rf value Colour observation Tentative ID 
of phytochemical Visible light UV 
light 
Detection with reagent 
Dragendorff Vanillin-H2SO4 ρ-anisaldehyde 
P1 0.11 - - - purple (+) - terpenoid 
P2 0.17 yellow (++) yellow (++) - - - xanthophyll 
P3 0.26 green (++) green (++) - - - cholrophyll 
P4 0.31 green (+++) green (+++) - - - chlorophyll 
P5 0.37 - - - - green (+++) flavonoid 
P6 0.41 green (+++) green (+++) - - - chlorophyll 
P7 0.47 - - - purple (+++) - terpenoid 
P8 0.74 - - - purple (+) - terpenoid 
 
Indication of colour intensity: Weak (+), Medium (++), Strong (+++), No colour observed (-) 
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Table 4.4: TLC profile of PA-C in mobile system hexane:acetone (7:3) 
Labelled 
compound 
Rf value Colour observation Tentative ID 
of phytochemical Visible light UV 
light 
Detection with reagent 
Dragendorff Vanillin-H2SO4 ρ-anisaldehyde 
C1 0.09 green (+++) green (+++) - - - chlorophyll 
C2 0.19 green (+) green (+) - - - chlorophyll 
C3 0.28 - - - purple (+) - terpenoid 
C4 0.43 green (+) green (+) - - - chlorophyll 
C5 0.50 green (++) green (++) - - - chlorophyll 
C6 0.64 green (++) green (++) - - - chlorophyll 
C7 0.71 green (+++) green (+++) - - - chlorophyll 
C8 0.78 - - - - blue (+) phenol 
C9 0.89 - - - - blue (+) phenol 
 
Indication of colour intensity: Weak (+), Medium (++), Strong (+++), No colour observed (-) 
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Table 4.5: TLC profile of PA-M in mobile system hexane:acetone (7:3) 
Labelled 
compound 
Rf value Colour observation Tentative ID 
of phytochemical Visible light UV 
light 
Detection with reagent 
Dragendorff Vanillin-H2SO4 ρ-anisaldehyde 
M1 0.14 green (++) green (++) - - - chlorophyll 
M2 0.20 green (+) green (+) - - - chlorophyll 
M3 0.51 green (++) green (++) - - - chlorophyll 
M4 0.59 green (++) green (++) - - purple (+) phenol 
M5 0.64 green (++) green (++) - - - chlorophyll 
M6 0.71 green (+) green (+) - purple (+) - terpenoid 
 
Table 4.6: TLC profile of PA-W in mobile system chloroform:methanol (1:9) 
Labelled 
compound 
Rf value Colour observation Tentative ID 
of phytochemical Visible light UV 
light 
Detection with reagent 
Dragendorff Vanillin-H2SO4 ρ-anisaldehyde 
W1 0.62 yellow (+) purple (++) - - purple (+) phenol 
W2 0.87 - purple (++) - purple (++) - terpenoid 
 
Indication of colour intensity: Weak (+), Medium (++), Strong (+++), No colour observed (-) 
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4.2.2 Gas chromatography mass spectrometry (GC-MS) 
In this study, phytochemical compounds present in PA-W and PA-M were identified 
using gas chromatography mass spectrometry. The analysis led to the identification of 
31 compounds in PA-W and 30 compounds in PA-M. In PA-W, organic acids, fatty 
acid, amino acid, amino alcohol, pyrimidine, sugar, and polyol were present. In PA-M, 
organic acids, amino alcohol, amino sugar, sugar, and polyol were present. Based on the 
chromatogram profile of GC-MS reflected in Figure 4.1, the peaks were marked with its 
retention time. The peak with the highest intensity comes at 27.55 min and 27.10 min 
for PA-W and PA-M, representing D-Glucose and D-Fuctose respectively. In both 
extracts, several identical compounds were detected. At 15.19 min and 15.16 min, 
glycerol was identified in PA-W and PA-M, as well as butanedioic acid at 16.53 min 
and 16.48 min, 1,4-butanediol at 20.51 min and 20.50 min, L-(-)-Arabitol at 24.51 min 
and 24.49 min, and 1-Cyclohexene-1-carboxylic acid at 26.23 min and 26.20 min, 
respectively. Glucopyranose was detected in both extract at 33.69 min. Cinnamic acid 
and benzoic acid were the phenols detected in PA-W at 28.34 min and 28.51 min 
respectively. In PA-M, benzoic acid was detected at 26.30 min. Compounds detected 
were summarized in Table 4.7 and Table 4.8. 
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Figure 4.1: GC-MS chromatogram profile of PA-W and PA-M
Pandanus amaryllifolius water extract 
Pandanus amaryllifolius methanol extract 
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Table 4.7: Phytochemical compounds in PA-W detected by using GC-MS 
No RT value Compound ID Group 
1 9.36 L-Valine Amino acid 
2 14.76 Silanamine Amino alcohol 
3 15.19 Glycerol Polyol 
4 16.53 Butanedioic acid Organic acid 
5 17.04 Butanedioic acid Organic acid 
6 17.17 Fumaric acid Organic acid 
7 18.32 Mesaconic acid Organic acid 
8 20.15 Malic acid Organic acid 
9 20.51 1,4-Butanediol Polyol 
10 20.90 Butanoic acid Organic acid 
11 24.06 Arabinitol Polyol 
12 24.51 L-(-)-Arabitol Polyol 
13 25.56 Ribonic acid Organic acid 
14 25.97 D-Xylofuranose Sugar 
15 26.11 D-(-)-Fructose Sugar 
16 26.23 1-Cyclohexene-1-carboxylic acid Organic acid 
17 27.31 D-Fructose Sugar 
18 27.43 Ribitol Polyol 
19 27.55 D-Glucose Sugar 
20 27.75 D-Galactose Sugar 
21 27.80 D-Glucose Sugar 
22 28.34 Cinnamic acid Organic acid 
23 28.51 Benzoic acid Organic acid 
24 29.05 á-D-Galactofuranose Sugar 
25 29.64 Mannose Sugar 
26 29.96 Hexadecanoic acid Fatty acid 
27 30.44 D-(+)-Xylose Sugar 
28 33.69 Glucopyranose Sugar 
29 35.61 Uridine Pyrimidine 
30 38.93 Thymol-á-d-glucopyranoside Organic acid 
31 43.17 Glycoside Sugar 
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Table 4.8: Phytochemical compounds in PA-M detected by using GC-MS 
No RT value Compound ID Group 
1 8.02 Propanoic acid Organic acid 
2 14.77 Silanamine Amino alcohol 
3 15.16 Glycerol Polyol 
4 16.48 Butanedioic acid Organic acid 
5 17.16 Fumaric acid Organic acid 
6 18.43 Mesaconic acid Organic acid 
7 20.18 Malic acid Organic acid 
8 20.50 1,4-Butanediol Polyol 
9 20.91 Butanoic acid Organic acid 
10 23.50 D-Ribose Sugar 
11 24.05 Arabinitol Polyol 
12 24.49 L-(-)-Arabitol Polyol 
13 25.95 D-Ribofuranose Sugar 
14 26.09 D-Fructose Sugar 
15 26.20 1-Cyclohexene-1-carboxylic acid Organic acid 
16 26.30 Benzoic acid Organic acid 
17 27.10 D-Fructose Sugar 
18 27.28 D-Fructose Sugar 
19 27.39 D-Galactose Sugar 
20 27.49 DGlucose Sugar 
21 27.72 D-Galactose Sugar 
22 27.77 D-Glucose Sugar 
23 28.02 D-Glucosamine Amino Sugar 
24 29.06 Ribonic acid Organic acid 
25 30.44 Inosose-2 Sugar 
26 33.61 Glycoside Sugar 
27 33.69 Glucopyranose Sugar 
28 34.54 D-Xylopyranose Sugar 
29 38.54 à-D-Galactopyranosiduronic acid Organic acid 
30 43.17 à-D-Galactopyranose Sugar 
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4.2.3 Liquid chromatography mass spectrometry (LC-MS) 
Phytochemical compounds present in PA-W were identified using liquid 
chromatography mass spectrometry. Three groups which are organic acids, ketone, and 
ester were present in PA-W. According to the chromatogram profile of LC-MS reflected 
in Figure 4.2, all four compounds were detected around 3 to 4 min of retention time. At 
3.02 min and 3.05 min, organic acids, L-galactonate and glucuronic acid were detected 
respectively. At 3.32 min, 2D-5-O-Methyl-2,3,5/4,6-pentahydroxycyclohexanone was 
detected. At 3.97 min, 4-Methyl-3-oxoadipate was detected. The identified compounds 
were listed in Table 4.9. 
 
Figure 4.2: LC-MS chromatogram profile of PA-W 
 
Table 4.9: Phytochemical compounds in PA-W detected by using LC-MS 
No RT value Compound ID Group 
1 3.02 L-Galactonate Organic acid 
2 3.05 Glucuronic acid Organic acid 
3 3.32 2D-5-O-Methyl-2,3,5/4,6-pentahydroxycyclohexanone Ketone 
4 3.97 4-Methyl-3-oxoadipate Ester 
. 
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4.3 Quantification of phenolic and flavonoid 
4.3.1 Total phenolic content (TPC) 
Total phenol content was expressed as gallic acid equivalent (mg GAE)/g of dry 
extract by comparing to a gallic acid standard curve (y=1.024x+0.21, R
2
=0.918). The 
result on the phenolic contents of P. amaryllifolius extracts obtained from the extraction 
by different solvents is depicted in Table 4.10. PA-W (12.88 ± 0.43 mg GAE/g dry 
extract) showed higher phenolic content as compared to PA-M (11.98 ± 0.40 mg GAE/g 
dry extract). It was then followed by PA-C (6.42 ± 0.49 mg GAE/g dry extract), PA-PE 
(3.65 ± 0.26 mg GAE/g dry extract), and finally PA-H (2.32 ± 0.27 mg GAE/g dry 
extract). The results of TPC showed that with increasing polarity of the solvent, the 
amount of phenolic compounds increased. 
 
4.3.2 Total flavonoid content (TFC) 
Total flavonoid content was expressed as quercetin equivalent (mg QE)/g of dry 
extract by referring to a standard curve of quercetin (y=0.283x+0.042, R
2
=0.957). The 
result on the flavonoid contents P. amaryllifolius extracts obtained from the extraction 
by different solvents is depicted in Table 4.10. PA-PE (15.02 ± 0.58 mg QE/g dry 
extract) possessed the highest flavonoid content followed by PA-H (11.66 ± 1.01 mg 
QE/g dry extract), PA-C (9.19 ± 1.53 mg QE/g dry extract), PA-M (9.07 ± 0.36 mg 
QE/g dry extract), and lastly PA-W (7.66 ± 1.10 mg QE/g dry extract). TFC was found 
higher in solvent with low polarity like PA-PE and PA-H. This was supported by TLC 
result as flavonoid was detected in PA-H (Rf value = 0.56) and PA-PE (Rf value = 0.37). 
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Table 4.10: TPC and TFC of P. amaryllifolius extracts 
Extracts TPC (mg GAE/g dry extract) TFC (mg QE/g dry extract) 
PA-H 2.32 ± 0.27 11.66 ± 1.01 
PA-PE 3.65 ± 0.26 15.02 ± 0.58 
PA-C 6.42 ± 0.49 9.19 ± 1.53 
PA-M 11.98 ± 0.40 9.07 ± 0.36 
PA-W 12.88 ± 0.43 7.66 ± 1.10 
Values are expressed as mean ± SEM (n = 3) 
 
 
4.4 Antioxidant activity 
The antioxidant activity determination of P. amaryllifolius extracts was conducted in 
four assays including DPPH radical scavenging activity, ferric reducing antioxidant 
power (FRAP) assay, metal chelating activity, and hydrogen peroxide scavenging 
activity. 
4.4.1 DPPH radical scavenging activity 
DPPH assay showed that antioxidant activity of P. amaryllifolius extracts was 
affected by the nature of solvent used. The result portrayed in Figure 4.3 indicates that 
IC50 was not achieved in all extracts when the same concentrations as the standard were 
applied. However, each extract possessed steady increase in the DPPH inhibition 
activity in the range of 10–240 g/mL. Based on the graph, PA-W showed the highest 
DPPH inhibition compared to others. This followed by PA-M, PA-C, PA-PE, and PA-
H. The IC50 value of ascorbic acid was 32.21 ± 1.54 g/mL (Table 4.11). The 
mechanism of this assay involves the formation of stable DPPH-H non radical form 
with the help of hydrogen donating antioxidants present in the extracts. The higher the 
amount of antioxidants in a sample, the higher the DPPH radical scavenging activity. 
The decrease in absorbance was detected at 517 nm. In this assay, the colour of the 
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reaction mixture turned from violet to pale yellow indicating positive results of 
scavenged DPPH radicals. 
 
Figure 4.3: Effect of P. amaryllifolius extracts on DPPH radical scavenging activity 
 
4.4.2 Ferric reducing antioxidant power (FRAP) assay 
The result of FRAP assay is expressed as FRAP value (mmol Fe
2+
/g of dry extract). 
Based on Table 4.11 the FRAP value of PA-H, PA-PE, PA-C, PA-M, and PA-W are 
21.21 ± 2.17, 28.64 ± 1.86, 35.91 ± 2.23, 64.39 ± 2.79, and 54.55 ± 1.48 mmol Fe
2+
/g of 
dry extract respectively. The reaction involves the formation of blue colour Fe
2+
-TPTZ 
form in the extracts after the antioxidants react with Fe
3+
-TPTZ complex. The highest 
FRAP value was detected in PA-M with 64.39 ± 2.79 mmol Fe
2+
/g of dry extract. The 
reducing ability of PA-H was the lowest as it only showed 21.21 ± 2.17 mmol Fe
2+
/g of 
dry extract. The reducing power was detected higher in polar solvent as compared to 
non polar solvent. 
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4.4.3 Metal chelating activity 
In metal chelating assay, each extract was unable to achieve IC50 using the same 
concentration as EDTA-Na2 standard. However, PA-W portrayed the strongest 
effectiveness in inhibiting the formation of Fe
2+
-ferrozine complex followed by PA-H, 
PA-M, PA-PE, and lastly PA-C (Figure 4.4). EDTA-Na2 achieved IC50 value of 11.23 ± 
2.13 g/mL (Table 4.11). IC50 value is defined as the concentration of test compound 
required to achieve 50% maximal inhibition. Even without the capability to obtain IC50, 
each extract did possess the ability to chelate metal ferrous ions within the concentration 
range of 5–160 g/mL. The decrease in absorbance was detected at 562 nm. From the 
results, the extracts showed metal chelating capability in dose dependent manner. 
 
Figure 4.4: Effect of P. amaryllifolius extracts on metal chelating activity 
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4.4.4 Hydrogen peroxide scavenging activity 
Hydrogen peroxide assay revealed that only PA-W and PA-M possess H2O2 
scavenging capability among four P. amaryllifolius extracts tested (Figure 4.5). Both 
extracts possessed hydrogen peroxide scavenging capability despite the fact that IC50 
was not achieved in the concentration range of 10–320 g/mL. PA-H and PA-C 
exhibited negative scavenging activity. PA-PE was not included since the yield of the 
crude extract was insufficient to proceed with this test. Ascorbic acid standard exhibited 
inhibition with IC50 value of 161.92 ± 2.03 g/mL (Table 4.11). 
 
Figure 4.5: Effect of P. amaryllifolius extracts on hydrogen peroxide scavenging 
activity 
 
Table 4.11: Antioxidant activities of P. amaryllifolius extracts 
Extracts DPPH 
(IC50 g/mL) 
FRAP 
(mmol Fe
2+
/g 
of dry extract) 
Metal chelating 
(IC50 g/mL) 
Hydrogen 
Peroxide 
(IC50 g/mL) 
PA-H >240 21.21 ± 2.17 >160 - 
PA-PE >240 28.64 ± 1.86 >160 - 
PA-C >240 35.91 ± 2.23 >160 - 
PA-M >240 64.39 ± 2.79 >160 >320 
PA-W >240 54.55 ± 1.48 >160 >320 
Standard 32.21 ± 1.54 - 11.23 ± 2.13 161.92 ± 2.03 
Values are expressed as mean ± SEM (n = 3) 
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4.5 In vitro xanthine oxidase inhibitory activity 
The ability of P. amaryllifolius extracts in inhibiting xanthine oxidase activity 
showed that only PA-W, PA-M, and PA-H possessed xanthine oxidase inhibition ability 
with PA-W having the highest activity (>100 g/mL) (Figure 4.6). IC50 however was 
not achieved in all three extracts except for allopurinol standard (IC50 = 9.30 ± 1.17 
g/mL) (Table 4.12). Since PA-W exhibited the most expressive outcome compared to 
other extracts, it was chosen to be administered on rats for in vivo xanthine oxidase 
activity. 
 
Figure 4.6: Effect of P. amaryllifolius extracts on in vitro xanthine oxidase 
inhibitory activity 
 
Table 4.12: In vitro xanthine oxidase inhibitory activity of P. amaryllifolius extracts 
Extracts IC50 (g/mL) 
PA-H >100 
PA-M >100 
PA-W >100 
Standard (Allopurinol) 9.30 ± 1.17 
Values are expressed as mean ± SEM (n = 3) 
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4.6 Correlation analysis 
From the Pearson correlation tests summarized in Table 4.12, TPC of P. 
amaryllifolius extracts showed positive significant correlation with DPPH radical 
scavenging activity (r = 0.972) and FRAP assay (r = 0.964) at 0.01 level. There was also 
positive significant correlation between TPC and hydrogen peroxide scavenging activity 
(r = 0.898) at 0.05 level. TPC demonstrated no correlation with metal chelating activity 
(r = 0.382) and in vitro xanthine oxidase inhibitory activity (r = 0.809). On the other 
hand, TFC showed negative correlation with all assays. 
Table 4.13: Correlation analysis 
Assays Correlation coefficients (r)
 
TPC TFC 
TPC - -0.786 
TFC -0.786 - 
DPPH radical scavenging activity 0.972
** 
-0.761 
FRAP assay 0.964
** 
-0.689 
Metal chelating activity 0.382 -0.350 
Hydrogen peroxide scavenging activity 0.898
* 
-0.691 
In vitro xanthine oxidase inhibitory activity 0.809 -0.684 
**
 Correlation is significant at the 0.01 level (2-tailed)  
*
 Correlation is significant at the 0.05 level (2-tailed) 
 
 
4.7 In vivo xanthine oxidase inhibitory activity 
4.7.1 Acute toxicity test 
Spraque Dawley rats of both sexes were fasted over-night before the administration 
of PA-W by oral gavage. After the study period of 14 days, it was found that the rats 
were safe at the dose of 2000 mg/kg. The rats showed normal behaviour pattern 
throughout the test. There were no signs of toxicity detected and zero occurrence of 
mortality in all rats. Based on this result, 1000 mg/kg (high dose) and 500 mg/kg (low 
dose) were selected for subsequent hypouricemic study. 
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4.7.2 Serum uric acid level 
Administration of oxonic acid potassium salt to rats (280 mg/kg body weight, i.p.) 
caused a significant (P < 0.001) increase in serum uric acid level of Group 3 rats (16.57 
± 2.98 mg/dL) when compared to normal control rats (Group 1) after two hours (Table 
4.13). Rats in Group 4 and 5 that received 1000 mg/kg and 500 mg/kg dose of PA-W 
portrayed significant (P < 0.001) decrease in the serum urate level up to 2.55 ± 2.23 
mg/dL and 6.08 ± 1.00 mg/dL, when compared to hyperuricemic control, respectively. 
This showed that PA-W possesses a dose-dependently hypouricemic action in 
hyperuricemic rats. Group 6 rats treated with allopurinol also significantly reduced the 
serum uric acid level in hyperuricemic rats and showed practically similar serum urate 
level as normal control group (Figure 4.7). 
Table 4.14: Serum uric acid level in hypouricemic study 
Group Condition Treatment Serum uric 
acid level (mg/dL) 
1  Normal rats Control 1.00 ± 0.00 
2  Normal rats High dose of PA-W  [1000 mg/kg] 1.80 ± 1.13
 
3 Hyperuricemic rats Control 16.57 ± 2.98
a 
4 Hyperuricemic rats High dose of PA-W [1000 mg/kg] 2.55 ± 2.23
b 
5 Hyperuricemic rats Low dose of PA-W [500 mg/kg] 6.08 ± 1.00
b 
6 Hyperuricemic rats Allopurinol [10 mg/kg] 1.72 ± 1.01
b 
Values are expressed as mean ± SEM (n = 6). 
a
 P < 0.001 significant when compared to normal control 
b
 P < 0.001 significant when compared to hyperuricemic control 
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Figure 4.7: Serum uric acid level in hypouricemic study. 
a
 P < 0.001 indicates 
significant difference when compared to normal control. 
b
 P < 0.001 indicates 
significant difference when compared to hyperuricemic control. 
 
4.7.3 Xanthine oxidase activity 
After whole blood samples were collected and serum separated, the serum was 
further analyzed using Xanthine Oxidase Activity Assay Kit (Sigma-Aldrich, USA). 
The results were expressed as nmole/min/mL = mu/mL, where one milliunit (mU) of 
XO is defined as the amount of enzyme that catalyzes the oxidation of xanthine yielding 
1.0 mmole of uric acid and hydrogen peroxide per minute at 25C. Results obtained 
from this analysis showed that Group 3 possessed the highest XO activity followed by 
Group 5 and Group 4. Group 1, Group 2 and Group 6 exhibited low XO activity (Figure 
4.8). When compared to normal control group (1.77 ± 0.43 mu/mL), serum of 
hyperuricemic rats in Group 3 displayed significant (P < 0.001) increase in XO activity 
with 10.72 ± 1.17 mu/mL (Table 4.14) because of the oxonic acid potassium salt. XO 
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activity in the serum of hyperuricemic rats treated with PA-W (high and low dose) and 
allopurinol were significantly reduced when compared to hyperuricemic control (Group 
3) with 3.84 ± 0.68 mu/mL, 6.35 ± 0.87 mu/mL, and 1.06 ± 0.21 mu/mL respectively. 
Table 4.15: Serum xanthine oxidase (XO) activity in hypouricemic study 
Group Condition Treatment XO activity 
(mu/mL) 
1 Normal rats Control 1.77 ± 0.43 
2 Normal rats High dose of PA-W  [1000 mg/kg] 1.46 ± 0.41
 
3 Hyperuricemic rats Control 10.72 ± 1.17
a 
4 Hyperuricemic rats High dose of PA-W [1000 mg/kg] 3.84 ± 0.68
b 
5 Hyperuricemic rats Low dose of PA-W [500 mg/kg] 6.35 ± 0.87
b 
6 Hyperuricemic rats Allopurinol [10 mg/kg] 1.06 ± 0.21
b 
Values are expressed as mean ± SEM (n = 6). 
a
 P < 0.001 significant when compared to normal control 
b
 P < 0.001 significant when compared to hyperuricemic control 
 
 
Figure 4.8: Serum xanthine oxidase (XO) activity in hypouricemic study. 
a
 P < 
0.001 indicates significant difference when compared to normal control. 
b
 P < 0.001 
indicates significant difference when compared to hyperuricemic control. 
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CHAPTER 5: DISCUSSION 
 
5.1 Preparation of plant extracts 
In this study, Pandanus amaryllifolius Roxb. plant underwent grounding process to 
become a powder using a blender. It was extracted using five different solvents, in order 
of increasing polarity which are hexane, petroleum ether, chloroform, methanol, and 
distilled water. The extraction process in 40C water bath appeared to increase extract 
yield. Study by Akowuah et al. (2009) stated 40C as the optimum temperature in the 
extraction of phenolic compounds and at higher temperature, low level of phenols was 
detected. This is possibly because increased temperature leads to the degradation of 
phenolic compounds. The moderate heat aids in concentrating the chemical compounds 
and amplifying the rate of extraction process. Out of these five solvents, water and 
methanol possessed an outstanding yield of crude extracts with 3.18 g and 2.26 g 
respectively. According to Ablat et al. (2014) polar solvents separate amino acids, 
hydrophilic molecules, and proteins whereas non polar solvents separate lipids. 
Havsteen (2002) stated that polar solvents can increase the efficiency of extraction 
process. 
 
5.2 Identification of the phytochemical compounds 
Plant based phytochemicals possess noteworthy impact in preventing numerous 
chronic diseases, convey beneficial outcome and perform crucial role in metabolic 
defects (Upadhyay & Dixit, 2015). The first step in detecting chemical constituents of 
P. amaryllifolius extracts in this research is using thin layer chromatography (TLC). The 
chemical compounds were separated and determined using spray reagents. The change 
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of colour on TLC plates confirmed the presence of specific compound. Different 
number of bands suggested that the nature of solvents used during extraction influences 
the kind of chemicals to be extracted. 
Gas chromatography mass spectrometry (GC-MS) was conducted to discover 
phytochemical compounds present in PA-W and PA-M. Wong et al. (2015) stated that 
GC-MS is the recommended method to be used in analyzing metabolites particularly in 
plant extracts, quantitatively and qualitatively. PA-W and PA-M were chosen because 
both extracts showed strong performance in antioxidant studies, in vitro xanthine 
oxidase inhibitory assay, and generated higher yield of crude extracts compared to three 
other extracts which are PA-H, PA-PE, and PA-C. Furthermore, more extracts are 
needed to proceed with subsequent animal study. In addition, study by Płotka-Wasylka 
et al. (2017) highlighted the significance of avoiding the use of organic solvents during 
extraction as it is harmful, consumes large amount of resources, and able to produce 
hazardous and poisonous waste. Therefore, these were the reasons to why only PA-M 
and PA-W were selected to detect the presence of phytochemicals in P. amaryllifolius 
using GC-MS. Based on the analysis, PA-W showed the total presence of 31 
compounds while PA-M with 30 compounds. The phytochemical compounds range 
from organic acid, fatty acid, amino acid, amino alcohol, pyrimidine, sugar, and polyol 
in PA-W. On the other hand, there were organic acid, amino alcohol, amino sugar, 
sugar, and polyol present in PA-M. In PA-W, two phenols were detected which are 
benzoic acid and cinnamic acid. In PA-M, one pheolic compound was detected which is 
benzoic acid. According to Azizan et al. (2012) GC-MS involves derivatization process 
that makes metabolites to be chemically volatile. Regular derivatization reagent, 
trimethylsilyl- (TMS) employed in this experiment gives a broad range of chemical 
detection. Chen et al. (2010) claimed that TMS is helpful for the detection of polyols, 
sugars and compounds that contain sulfur. 
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Liquid chromatography mass spectrometry (LC-MS) was carried out to qualitatively 
detect phytochemical compounds in PA-W. The analysis was conducted in negative 
ionization mode. Several studies used negative mode for LC-MS detection of phenolic 
compounds (Chen et al., 2012; Zhu et al., 2012; Bataglion et al., 2014; Junqueira-
Gonçalves et al., 2015; Oszmiański et al., 2015). Sun et al. (2013) stated that negative 
ionization mode showed better sensitivity and reproducibility than positive mode in full 
scan mass spectra. Study by Kolniak-Ostek & Oszmiański (2015) showed that major 
phenolic compounds such as flavonols, flavones, phenolic acids, hydrochalcones, 
catechins and procyanidins were putatively detected in negative ionization mode. Out of 
152 compounds detected, the negative ionization mode used in the identification process 
revealed four known compounds which are L-galactonate, glucuronic acid, 2D-5-O-
methyl-2,3,5/4,6-pentahydroxycyclohexanone, and 4-methyl-3-oxoadipate. These four 
compounds were not the same as the ones reported in previous phytochemical studies of 
P. amaryllifolius. For instances, 2AP, the major compound that impart pleasant smell in 
P. amaryllifolius (Yahya et al., 2010) and phenolics such as phenolic acids (gallic acid) 
and flavonoids (catechin, kaempferol and naringin) (Ghasemzadeh & Jaafar, 2013). 
There are several phytochemical compounds that perform well as xanthine oxidase 
inhibitor. Wan et al. (2016) showed that verbascoside, a polyphenol, significantly 
inhibited xanthine oxidase activity and reduced uric acid in hyperuricemic model. Other 
phenolics that showed potent inhibitory effect of xanthine oxidase are flavone eupatilin 
(Lin et al., 2014) as well as phenolic acids (gallic acid, chlorogenic acid, caffeic acid, 
and ellagic acid) and flavonoids (catechin, rutin, luteolin, quercetin, epicatechin, and 
apigenin) (Irondi et al., 2016). From the results obtained through GC-MS and LC-MS, it 
was revealed that most of the compounds detected in both extracts were comparatively 
similar. The organic acids which mainly comprised of carboxylic acids as well as sugars 
were found abundant in both extracts. 
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5.3 Quantification of phenolic and flavonoid 
Total phenolic content (TPC) and total flavonoid content (TFC) of P. amaryllifolius 
extracts were determined to quantify total phenolics and flavonoids available in each 
extract. According to Karimi et al. (2011) phenolics are prominent secondary 
metabolites that exhibits extensive pharmacological actions while flavonoids are crucial 
secondary metabolites that possesses a number of bioactive compounds in plants. TPC 
was expressed as gallic acid equivalent by referring to a standard curve of gallic acid 
(y=1.024x+0.21, R
2
=0.918). On the other hand, TFC was expressed as quercetin 
equivalent using standard curve of quercetin (y=0.283x+0.042, R
2
=0.957). PA-W 
possessed the highest TPC while the highest TFC is represented by PA-PE. Based on 
Pearson correlation test carried out, TPC and TFC demonstrated negative correlation. 
Both of these experiments did not reflect on one another. This is because the amount of 
flavonoids was not in agreement with the amount of phenols represented by each 
extract. TFC was found higher in extracts of non polar solvents. On the other hand, TPC 
was found higher in extracts of polar solvents. This supports the study by Ablat et al. 
(2014) as they found that the amount of TPC increased as the polarity of the solvent. 
According to Kim et al. (2012) the extractants used in the extraction process had an 
impact on the TPC of extracts. Based on the detection of phytochemical compounds 
using GC-MS, the highest phenolic content in PA-W may be contributed by the 
presence of benzoic acid and cinnamic acid. Meanwhile, the present of benzoic acid 
may lead to the second highest phenolic content rank represented by PA-M. 
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5.4 Antioxidant activity 
According to Sáyago-Ayerdi et al. (2007) more than one method is required to assess 
antioxidant potential. Determination of antioxidant activity was carried out using DPPH 
radical scavenging activity, ferric reducing antioxidant power (FRAP) assay, metal 
chelating activity, and hydrogen peroxide scavenging activity. According to Oskoueian 
et al. (2011) antioxidants aid in obstructing oxidative damage and phenolics can exhibit 
higher activity than vitamins, but its activity relies on their chemical structure and 
number of hydroxyl groups. Maltas et al. (2011) stated that high amount of 
phytochemicals such as phenolics, flavonoids, terpenoids and other result in high 
antioxidant activity. In this study, the antioxidant activities of P. amaryllifolius extracts 
were affected by the nature of solvent used. 
Bajpai et al. (2017) claimed that DPPH scavenging activity is performed extensively 
by researchers to estimate antioxidant capabilities within short period of time than other 
assays. In this study, DPPH assay revealed PA-W as the most potent candidate in 
scavenging DPPH free radicals. From the result obtained, P. amaryllifolius extracts 
showed increasing activity with increasing polarity of the solvent. This could be linked 
with the TPC results because based on Pearson correlation test conducted, there is a 
significant correlation between TPC and DPPH assay. Therefore, this suggests that 
phenolic compounds may contribute to DPPH radical scavenging effects in P. 
amaryllifolius extracts. Thus, this showed that extraction using different solvents lead to 
different capability of antioxidant scavenging activity due to varying phytochemical 
composition present in each extract. Few other studies also proved a significant 
correlation between TPC and DPPH assay (Ng et al., 2012; Tiveron et al., 2012; Ablat 
et al., 2014; Saha & Verma, 2016). 
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Ferric reducing antioxidant power (FRAP) assay is measured via the principle of 
reducing ferric (III) to ferrous (II) ion (Sahgal et al., 2009). FRAP assay of P. 
amaryllifolius extracts. also exhibited increasing activity as the solvent polarity 
increased. Just like DPPH, this result associated with TPC as FRAP assay showed 
significant correlation with TPC. This result is in agreement with other studies that 
discovered positive significant correlation between TPC and FRAP assay (Gan et al., 
2013; Ku et al., 2014; Hanis Mastura et al., 2017). Study by Kabouche et al. (2007) 
stated that a few terpenoids displayed effective reducing power in FRAP aasay. As 
terpenoids were detected in all five extracts during TLC experiment, this advocates the 
role of terpenoids in P. amaryllifolius as reductants that donates an electron, 
transforming Fe
3+ 
to Fe
2+
. 
Metal chelating activity evaluates the ability of antioxidant in chelating ferrous ion. 
The system is dose dependent whereby higher sample concentration results in higher 
chelating activity. In our body, ferrous ion (Fe
2+
) leads to the formation of reactive 
oxygen species which can harm body cells (Yamaguchi et al., 1988). The metal 
chelating mechanism involves the formation of ferrous-ferrozine complex from the 
chelating activity of Fe
2+ 
by extracts. In this assay P. amaryllifolius extracts were 
studied for its ability to compete with ferrozine for ferrous ion and the chelating ability 
was measured via absorbance detected at 562 nm with the formation of Fe
2+
- ferrozine 
complex. Andjelković et al. (2006) stated that phenolics in plants may not be able to 
chelate iron as good as EDTA. The order of ferrous ion chelating activity is: PA-W > 
PA-H > PA-M > PA-PE > PA-C. The result from this assay showed no correlation with 
TPC. This implies that the amount of phenolics in P. amaryllifolius extracts did not 
affect metal chelating activity. Study by Taherkhani (2016) also found that TPC and 
metal chelation activity possessed no correlation. On the other hand, metal chelating 
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activity showed negative correlation with TFC. This suggests that flavonoids do not 
appear to be effective ferrous ion chelators. 
Hydrogen peroxide is non reactive, however it may possess toxic effect to cells by 
transforming into hydroxyl radicals that reacts with biomolecules. This results in the 
destruction of body tissues as well as the death of cells (Khan et al., 2012). Result from 
this assay proposed that there is a significant correlation between TPC and hydrogen 
peroxide scavenging activity, similar to DPPH assay. This indicates that high phenolic 
content lead to high scavenging activity of hydroxyl radicals. A number of studies also 
revealed the presence of strong correlation between TPC and hydrogen peroxide 
scavenging activity (Khan et al., 2012; Chakraborty et al., 2013; Kumar et al., 2017). 
Meanwhile, TFC exhibited negative correlation with H2O2 scavenging activity. Tiveron 
et al. (2012) stated that each penolic and non-phenolic compounds possessed varying 
antioxidant potential by which high amount of particular compounds will not 
necessarily assure potent antioxidant effects. 
 
5.5 In vitro xanthine oxidase inhibitory activity 
In vitro study was conducted to determine the ability of P. amaryllifolius extracts to 
retard the activity of xanthine oxidase enzyme. According to Umamaheswari et al. 
(2009) phenols and flavonoids present in extracts have the ability to express inhibitory 
activity of xanthine oxidase. The evaluation was conducted at concentration range of 
6.25–100 g/mL. The highest xanthine oxidase inhibitory activity was shown by PA-W, 
followed by PA-M and lastly PA-H. Two other extracts which are PA-PE and PA-C 
have shown no inhibition activity. This is possibly because of inadequate specific 
compounds that possess xanthine oxidase inhibition capability in the extracts (Azmi et 
al., 2012).  
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5.6 In vivo xanthine oxidase inhibitory activity 
PA-W was selected and screened for in vivo hypouricemic activity. Azmi et al. 
(2012) stated that in a large scale, high amount of solvents are needed and it is wiser to 
use the most economical solvent in the extraction process while considering its safety 
measure. Since methanol is toxic to the body as it can interfere the physiological acid-
base balance, solvents with lower toxicity with same potential should be utilized 
wherever possible. Water as the world‘s universal solvent is crucial for every living 
thing. It is easily obtainable, pretty well significant, and cost effective. 
In hypouricemic study, the ability of PA-W to impede hyperuricemia induced by 
oxonic acid potassium salt was studied using Spraque Dawley rats. Based on the results 
obtained, PA-W exhibited significant hypouricemic activity for both high (1000 mg/kg) 
and low (500 mg/kg) dosage. Based on the results, allopurinol still possessed the most 
outstanding effect on both in vitro xanthine oxidase inhibitory activity and in vivo 
hypouricemic activity. Allopurinol is widely used and easily available to treat 
hyperuricemia, gout and other inflammatory ailments. However, due to hypersensitivity, 
intolerance, and failure of the treatment on certain patients (Lü et al., 2013) alternative 
therapeutic agents especially xanthine inhibitors in natural compounds are 
recommended as it displays fewer side effects (Wong et al., 2014). In this experiment, 
dose-dependent PA-W possessed practically comparable effect with allopurinol in 
reducing serum uric acid level and XO activity. Umamaheswari et al. (2007) stated that 
the presence of phytoconstituents in extracts along with their anti-inflammatory and 
antioxidant activities manifest a notable XO inhibitory activity and hypouricemic 
activity. However, TPC showed no correlation with in vitro xanthine oxidase inhibitory 
activity in this study. According to Kostić et al. (2015) the way to treat gout and 
hyperuricemia is by elevating the uric acid excretion or minimizing the production of 
uric acid. Since PA-W has significantly and successfully reduced the uric acid level and 
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inhibited XO activity in hyperuricemic rats serum, this indicates that the use of PA-W 
may be beneficial in gout and hyperuricemia therapy. This contributes to the beginning 
of further examination on this species to isolate its active constituents and invention of 
drug. 
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CHAPTER 6: CONCLUSION 
 
Pandanus amaryllifolius Roxb. extracts extracted with hexane, petroleum ether, 
chloroform, methanol and distilled water contain a number of phytochemicals which 
include phenolic and flavonoid compounds. These bioactive compounds possess 
antioxidant activities and display an outstanding impact in healing numerous diseases. 
In antioxidant assays, extracts that were extracted using different solvent polarity 
displayed different level of antioxidant capability. PA-W acts as the most potent 
candidate in this research study. It exhibited the highest effectiveness in both 
antioxidant activity and xanthine oxidase inhibitory activity compared to other extracts. 
PA-W and PA-PE contributed the highest TPC and TFC, respectively. PA-W possessed 
the highest inhibition in DPPH radical scavenging activity, metal chelating activity, and 
hydrogen peroxide scavenging activity. PA-M showed the most potent reducing power 
in FRAP assay. In vitro xanthine oxidase inhibitory activity displayed PA-W as the 
strongest xanthine oxidase inhibitor. PA-W also had significantly reduced serum uric 
acid level and inhibited xanthine oxidase activity in in vivo xanthine oxidase inhibitory. 
The results obtained from this study suggest P. amaryllifolius as a novel xanthine 
oxidase inhibitor derived from natural sources that shows potent activity and low 
toxicity in the future. 
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APPENDIX 
Appendix A: Thin layer chromatography (TLC) 
TLC plates observed under visible light. From left to right: PA-H, PA-PE, PA-C, PA-
M, PA-W. 
 
TLC plates observed under UV light. From left to right: PA-H, PA-PE, PA-C, PA-M, 
PA-W. 
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Appendix B: Gas chromatography mass spectrometry (GC-MS) 
LC-MS chromatogram profile of L-Galactonate 
 
LC-MS chromatogram profile of Glucuronic acid 
 
LC-MS chromatogram profile of 2D-5-O-methyl-2,3,5/4,6-pentahydroxycyclohexanone 
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LC-MS chromatogram profile of 4-methyl-3-oxoadipate 
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Appendix C: Total phenolic content 
Extracts 
Absorbance at 740 nm 
Mean TPC SEM Abs 1 Abs 2 Abs 3 
PA-H 0.312 0.328 0.346 0.329 2.32 0.27 
PA-PE 0.399 0.38 0.412 0.397 3.65 0.26 
PA-C 0.574 0.525 0.517 0.539 6.42 0.49 
PA-M 0.852 0.807 0.811 0.823 11.98 0.40 
PA-W 0.899 0.863 0.846 0.869 12.88 0.43 
 
 
Gallic acid standard curve 
 
 
 
 
 
 
 
y = 1.024x + 0.2103 
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Appendix D: Total flavonoid content 
Extracts 
Absorbance at 510 nm 
Mean TFC SEM Abs 1 Abs 2 Abs 3 
PA-H 0.115 0.108 0.101 0.108 11.66 1.01 
PA-PE 0.131 0.123 0.127 0.127 15.02 0.58 
PA-C 0.102 0.098 0.082 0.094 9.19 1.53 
PA-M 0.091 0.096 0.093 0.093 9.07 0.36 
PA-W 0.087 0.092 0.077 0.085 7.66 1.10 
 
 
Quercetin standard curve 
 
 
 
 
 
 
 
y = 0.2836x + 0.0421 
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Appendix E: DPPH radical scavenging activity 
Ascorbic acid (standard) 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.704 0.718 0.701 0.708 0.007 0.00 1.05 
10 0.610 0.620 0.603 0.611 0.007 13.71 0.98 
20 0.477 0.492 0.484 0.484 0.006 31.58 0.86 
40 0.254 0.281 0.270 0.268 0.011 62.09 1.54 
80 0.078 0.084 0.068 0.076 0.006 89.21 0.90 
160 0.061 0.069 0.055 0.062 0.005 91.30 0.77 
240 0.065 0.051 0.053 0.056 0.006 92.09 0.91 
 
PA-H 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.337 0.335 0.333 0.335 0.002 0.00 0.49 
10 0.321 0.324 0.334 0.326 0.006 2.56 1.66 
20 0.320 0.315 0.331 0.322 0.007 3.87 2.01 
40 0.321 0.332 0.328 0.327 0.005 2.49 1.41 
80 0.318 0.326 0.305 0.316 0.009 5.62 2.65 
160 0.300 0.289 0.287 0.292 0.006 12.94 1.78 
240 0.295 0.281 0.290 0.289 0.005 13.87 1.62 
 
PA-PE 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.337 0.335 0.333 0.335 0.002 0.00 0.49 
10 0.319 0.332 0.326 0.326 0.006 2.84 1.65 
20 0.330 0.329 0.334 0.331 0.002 1.19 0.64 
40 0.325 0.335 0.310 0.323 0.010 3.51 3.03 
80 0.299 0.291 0.305 0.298 0.006 10.97 1.67 
160 0.295 0.268 0.290 0.284 0.012 15.17 3.48 
240 0.262 0.261 0.279 0.267 0.009 20.26 2.59 
 
PA-C 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.337 0.335 0.333 0.335 0.002 0.00 0.49 
10 0.324 0.317 0.329 0.323 0.005 3.49 1.51 
20 0.316 0.325 0.334 0.325 0.007 3.13 2.19 
40 0.316 0.320 0.312 0.316 0.003 5.82 0.97 
80 0.313 0.321 0.305 0.313 0.007 6.67 2.01 
160 0.287 0.291 0.277 0.285 0.006 14.98 1.71 
240 0.254 0.257 0.264 0.258 0.004 23.03 1.25 
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PA-M 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.337 0.335 0.333 0.335 0.002 0.00 0.49 
10 0.321 0.330 0.315 0.322 0.006 3.98 1.78 
20 0.318 0.306 0.320 0.314 0.006 6.17 1.78 
40 0.314 0.313 0.305 0.310 0.004 7.41 1.20 
80 0.281 0.285 0.261 0.276 0.010 17.71 3.13 
160 0.265 0.256 0.250 0.257 0.006 23.26 1.89 
240 0.232 0.221 0.229 0.227 0.005 32.19 1.45 
 
PA-W 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.337 0.335 0.333 0.335 0.002 0.00 0.49 
10 0.316 0.325 0.314 0.318 0.004 4.99 1.32 
20 0.314 0.311 0.320 0.315 0.004 6.03 1.14 
40 0.311 0.300 0.304 0.305 0.005 9.10 1.36 
80 0.263 0.263 0.274 0.267 0.005 20.32 1.51 
160 0.229 0.237 0.220 0.229 0.007 31.78 2.00 
240 0.205 0.194 0.207 0.202 0.006 39.75 1.68 
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Appendix F: Ferric reducing antioxidant power (FRAP) assay 
Extracts 
Absorbance at 595 nm 
Mean FRAP value SEM Abs 1 Abs 2 Abs 3 
PA-H 0.312 0.328 0.346 0.329 2.32 0.27 
PA-PE 0.399 0.38 0.412 0.397 3.65 0.26 
PA-C 0.574 0.525 0.517 0.539 6.42 0.49 
PA-M 0.852 0.807 0.811 0.823 11.98 0.40 
PA-W 0.899 0.863 0.846 0.869 12.88 0.43 
 
 
Ferrous sulfate standard curve 
 
 
 
 
 
 
 
y = 0.0445x + 0.0107 
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Appendix G: Metal chelating activity 
EDTA-Na2 (standard) 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
5 1.325 1.299 1.421 1.348 0.053 20.91 3.08 
10 0.895 0.978 0.964 0.946 0.036 44.52 2.13 
20 0.324 0.353 0.360 0.346 0.016 79.73 0.92 
40 0.127 0.181 0.101 0.136 0.033 92.02 1.96 
80 0.063 0.076 0.048 0.062 0.011 96.35 0.67 
160 0.064 0.022 0.032 0.039 0.018 97.70 1.07 
 
PA-H 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
10 1.439 1.468 1.422 1.443 0.019 15.36 1.12 
20 1.384 1.341 1.362 1.362 0.018 20.10 1.03 
40 1.301 1.294 1.322 1.306 0.012 23.42 0.68 
80 1.169 1.186 1.197 1.184 0.011 30.56 0.67 
160 1.102 1.057 1.131 1.097 0.030 35.68 1.79 
 
PA-PE 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
10 1.622 1.636 1.663 1.640 0.017 3.78 1.00 
20 1.600 1.526 1.595 1.574 0.034 7.70 2.00 
40 1.480 1.402 1.461 1.448 0.033 15.08 1.94 
80 1.407 1.373 1.422 1.400 0.020 17.86 1.20 
160 1.221 1.268 1.241 1.243 0.019 27.07 1.13 
 
PA-C 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
10 1.566 1.555 1.573 1.565 0.008 8.23 0.45 
20 1.577 1.540 1.512 1.543 0.027 9.49 1.56 
40 1.528 1.532 1.540 1.533 0.005 10.06 0.31 
80 1.566 1.533 1.541 1.547 0.014 9.27 0.82 
160 1.482 1.443 1.471 1.465 0.016 14.04 0.96 
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PA-M 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
10 1.536 1.564 1.513 1.537 0.021 9.82 1.24 
20 1.501 1.529 1.522 1.517 0.012 11.00 0.70 
40 1.444 1.433 1.490 1.455 0.025 14.63 1.44 
80 1.285 1.293 1.236 1.271 0.025 25.45 1.48 
160 1.143 1.172 1.136 1.150 0.016 32.54 0.93 
 
PA-W 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.685 1.723 1.706 1.705 0.015 0.00 0.90 
10 1.603 1.631 1.600 1.611 0.014 5.50 0.83 
20 1.472 1.459 1.548 1.493 0.039 12.44 2.29 
40 1.296 1.329 1.233 1.286 0.040 24.56 2.32 
80 1.126 1.106 1.134 1.122 0.012 34.18 0.69 
160 0.938 0.907 0.956 0.933 0.020 45.25 1.19 
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Appendix H: Hydrogen peroxide scavenging activity 
Ascorbic acid (standard) 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.699 0.727 0.681 0.702 0.019 0.00 2.69 
10 0.657 0.638 0.641 0.645 0.008 8.12 1.19 
20 0.630 0.608 0.622 0.620 0.009 11.72 1.29 
40 0.571 0.587 0.571 0.576 0.008 17.94 1.07 
80 0.521 0.540 0.503 0.521 0.015 25.77 2.15 
160 0.355 0.338 0.373 0.355 0.014 49.41 2.03 
320 0.177 0.197 0.185 0.186 0.008 73.47 1.17 
 
PA-H 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.699 0.727 0.681 0.702 0.019 0.00 2.69 
10 0.721 0.744 0.730 0.732 0.009 -4.18 1.35 
20 0.726 0.739 0.754 0.740 0.011 -5.32 1.63 
40 0.770 0.791 0.793 0.785 0.010 -11.72 1.48 
80 0.795 0.785 0.800 0.793 0.006 -12.96 0.89 
160 0.798 0.822 0.807 0.809 0.010 -15.19 1.41 
320 0.799 0.829 0.848 0.825 0.020 -17.51 2.87 
 
PA-C 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.699 0.727 0.681 0.702 0.019 0.00 2.69 
10 0.777 0.741 0.765 0.761 0.015 -8.35 2.13 
20 0.791 0.783 0.797 0.790 0.006 -12.53 0.82 
40 0.808 0.829 0.859 0.832 0.021 -18.46 2.98 
80 0.865 0.880 0.817 0.854 0.027 -21.59 3.83 
160 0.900 0.911 0.929 0.913 0.012 -30.04 1.70 
320 0.944 0.962 0.940 0.949 0.010 -35.07 1.36 
 
PA-M 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.699 0.727 0.681 0.702 0.019 0.00 2.69 
10 0.701 0.688 0.672 0.687 0.012 2.18 1.69 
20 0.671 0.660 0.669 0.667 0.005 5.08 0.68 
40 0.646 0.659 0.630 0.645 0.012 8.16 1.69 
80 0.635 0.624 0.639 0.633 0.006 9.92 0.90 
160 0.620 0.602 0.616 0.613 0.008 12.77 1.10 
320 0.584 0.570 0.606 0.587 0.015 16.47 2.11 
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PA-W 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 0.699 0.727 0.681 0.702 0.019 0.00 2.69 
10 0.688 0.693 0.707 0.696 0.008 0.90 1.14 
20 0.660 0.655 0.673 0.663 0.008 5.65 1.08 
40 0.640 0.652 0.657 0.650 0.007 7.50 1.02 
80 0.596 0.611 0.606 0.604 0.006 13.95 0.89 
160 0.599 0.591 0.564 0.585 0.015 16.75 2.13 
320 0.521 0.553 0.527 0.534 0.014 24.02 1.98 
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Appendix I: In vitro xanthine oxidase inhibitory activity 
Allopurinol (standard) 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 0.828 0.891 0.875 0.865 0.027 32.66 2.08 
12.5 0.401 0.426 0.437 0.421 0.015 67.19 1.17 
25 0.386 0.341 0.355 0.361 0.019 71.91 1.46 
50 0.221 0.282 0.269 0.257 0.026 79.96 2.04 
100 0.195 0.164 0.185 0.181 0.013 85.88 1.01 
 
PA-H 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 1.278 1.231 1.263 1.257 0.020 2.08 1.53 
12.5 1.223 1.143 1.192 1.186 0.033 7.63 2.56 
25 1.101 1.026 0.991 1.039 0.046 19.06 3.57 
50 0.946 0.977 0.982 0.968 0.016 24.58 1.24 
100 0.916 0.921 0.957 0.931 0.018 27.47 1.42 
 
PA-PE 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 1.329 1.292 1.286 1.302 0.019 -1.43 1.48 
12.5 1.378 1.363 1.346 1.362 0.013 -6.10 1.02 
25 1.391 1.379 1.436 1.402 0.025 -9.19 1.91 
50 1.471 1.436 1.448 1.452 0.015 -13.06 1.13 
100 1.555 1.507 1.493 1.518 0.027 -18.25 2.07 
 
PA-C 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 1.291 1.306 1.278 1.292 0.011 -0.60 0.89 
12.5 1.304 1.312 1.316 1.311 0.005 -2.08 0.39 
25 1.317 1.327 1.320 1.321 0.004 -2.91 0.33 
50 1.345 1.333 1.329 1.336 0.007 -4.02 0.53 
100 1.332 1.347 1.359 1.346 0.011 -4.83 0.86 
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PA-M 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 1.252 1.188 1.171 1.204 0.035 6.26 2.72 
12.5 1.130 1.154 1.113 1.132 0.017 11.81 1.31 
25 0.995 1.083 1.001 1.026 0.040 20.07 3.13 
50 0.957 0.923 0.930 0.937 0.015 27.05 1.14 
100 0.873 0.846 0.895 0.871 0.020 32.14 1.56 
 
PA-W 
Concentration (g/mL) Abs 1 Abs 2 Abs 3 Mean SD % activity SEM 
0 1.286 1.257 1.309 1.284 0.021 0.00 1.66 
6.25 1.107 1.118 1.136 1.120 0.012 12.75 0.93 
12.5 0.979 1.010 0.995 0.995 0.013 22.53 0.99 
25 0.924 0.891 0.889 0.901 0.016 29.80 1.25 
50 0.777 0.808 0.795 0.793 0.013 38.21 0.99 
100 0.685 0.693 0.651 0.676 0.018 47.33 1.42 
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Appendix J: Pearson correlation test 
Correlations 
 TPC TFC DPPH FRAP METAL H202 XO_INVITRO 
TPC Pearson Correlation 1 -.786 .972
**
 .964
**
 .382 .898
*
 .809 
Sig. (2-tailed)  .115 .006 .008 .525 .039 .097 
N 5 5 5 5 5 5 5 
TFC Pearson Correlation -.786 1 -.761 -.689 -.350 -.691 -.684 
Sig. (2-tailed) .115  .135 .198 .563 .196 .203 
N 5 5 5 5 5 5 5 
DPPH Pearson Correlation .972
**
 -.761 1 .898
*
 .300 .884
*
 .728 
Sig. (2-tailed) .006 .135  .038 .624 .047 .164 
N 5 5 5 5 5 5 5 
FRAP Pearson Correlation .964
**
 -.689 .898
*
 1 .262 .785 .723 
Sig. (2-tailed) .008 .198 .038  .671 .115 .168 
N 5 5 5 5 5 5 5 
METAL Pearson Correlation .382 -.350 .300 .262 1 .707 .849 
Sig. (2-tailed) .525 .563 .624 .671  .182 .069 
N 5 5 5 5 5 5 5 
H202 Pearson Correlation .898
*
 -.691 .884
*
 .785 .707 1 .943
*
 
Sig. (2-tailed) .039 .196 .047 .115 .182  .016 
N 5 5 5 5 5 5 5 
XO_INVITRO Pearson Correlation .809 -.684 .728 .723 .849 .943
*
 1 
Sig. (2-tailed) .097 .203 .164 .168 .069 .016  
N 5 5 5 5 5 5 5 
**. Correlation is significant at the 0.01 level (2-tailed). 
*. Correlation is significant at the 0.05 level (2-tailed). 
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Appendix K: Serum uric acid level 
Treatment groups Serum uric acid level (mg/dL) Mean SEM 
1 2 3 4 5 6 
G1 1.0 1.0 1.0 1.0 1.0 1.0 1.00 0.00 
G2 3.5 1.0 1.0 3.3 1.0 1.0 1.80 1.13 
G3 12.5 17.7 16.9 16.1 14.2 22.0 16.57 2.98 
G4 4.9 1.0 1.0 1.0 1.0 6.4 2.55 2.23 
G5 7.1 5.1 6.3 5.8 7.5 4.7 6.08 1.00 
G6 1.0 3.1 3.2 1.0 1.0 1.0 1.72 1.01 
 
Multiple Comparisons 
Dependent Variable:   UAlevel   
Dunnett t (2-sided)
a
   
(I) Treatment (J) Treatment 
Mean 
Difference  
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
HD only N .8000 1.07054 .912 -3.6992 5.2992 
PO N 15.5667* 1.07054 .000 11.0675 20.0659 
PO+HD N 1.5500 1.07054 .470 -2.9492 6.0492 
PO+LD N 5.0833* 1.07054 .000 .5841 9.5825 
PO+allopurinol N .7167 1.07054 .941 -3.7825 5.2159 
 
Multiple Comparisons 
Dependent Variable:   UAlevel   
Dunnett t (2-sided)
a
   
(I) Treatment (J) Treatment 
Mean 
Difference  
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
HD PO -14.7667* 1.07054 .000 -19.2659 -10.2675 
N PO -15.5667* 1.07054 .000 -20.0659 -11.0675 
PO+HD PO -14.0167* 1.07054 .000 -18.5159 -9.5175 
PO+LD PO -10.4833* 1.07054 .000 -14.9825 -5.9841 
PO+allopurinol PO -14.8500* 1.07054 .000 -19.3492 -10.3508 
Based on observed means. 
 The error term is Mean Square (Error) = 3.438. 
*. The mean difference is significant at the .001 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Appendix L: Xanthine oxidase activity 
Treatment  
groups 
Abs 1 Abs 2 Abs 3 Abs 4 Abs 5 Abs 6 Mean XO  
activity 
SEM 
G1 0.049 0.063 0.029 0.060 0.044 0.064 0.051 1.77 0.43 
G2 0.022 0.055 0.051 0.036 0.053 0.038 0.042 1.46 0.41 
G3 0.288 0.340 0.258 0.291 0.343 0.346 0.311 10.72 1.17 
G4 0.093 0.140 0.106 0.083 0.122 0.127 0.112 3.84 0.68 
G5 0.193 0.169 0.157 0.198 0.160 0.229 0.184 6.35 0.87 
G6 0.029 0.019 0.039 0.031 0.034 0.033 0.031 1.06 0.21 
 
Multiple Comparisons 
Dependent Variable:   XOactivity   
Dunnett t (2-sided)
a
   
(I) Treatment (J) Treatment 
Mean 
Difference  
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
HD only N -.3075 .44543 .934 -2.1795 1.5646 
PO N 8.9511* .44543 .000 7.0791 10.8232 
PO+HD N 2.0776* .44543 .000 .2056 3.9496 
PO+LD N 4.5805* .44543 .000 2.7084 6.4525 
PO+allopurinol N -.7098 .44543 .381 -2.5818 1.1623 
 
Multiple Comparisons 
Dependent Variable:   XOactivity   
Dunnett t (2-sided)
a
   
(I) Treatment (J) Treatment 
Mean 
Difference  
(I-J) Std. Error Sig. 
99.9% Confidence Interval 
Lower Bound Upper Bound 
HD PO -9.2586* .44543 .000 -11.1306 -7.3866 
N PO -8.9511* .44543 .000 -10.8232 -7.0791 
PO+HD PO -6.8736* .44543 .000 -8.7456 -5.0015 
PO+LD PO -4.3707* .44543 .000 -6.2427 -2.4987 
PO+allopurinol PO -9.6609* .44543 .000 -11.5329 -7.7889 
Based on observed means. 
 The error term is Mean Square (Error) = .595. 
*. The mean difference is significant at the .001 level. 
a. Dunnett t-tests treat one group as a control, and compare all other groups against it. 
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Appendix M: Animal Use Protocol (AUP) approval letter 
 
